{
  "metadata": {
    "title": "Click-binol-phosphoric acid catalysts in intramolecular enantioselective oxidative C<ce:glyph name=sbnd></ce:glyph>H-bond functionalization",
    "authors": "; ; ",
    "journal": "Journal of Molecular Catalysis A: Chemical",
    "date": "2017-01-31",
    "doi": "10.1016/j.molcata.2016.09.006",
    "abstract": "",
    "uri": "https://api.elsevier.com/content/article/pii/S1381116916303788",
    "pii": "S1381116916303788"
  },
  "fulltext": {
    "full-text-retrieval-response": {
      "scopus-eid": "2-s2.0-84997416712",
      "originalText": "serial JL 271358 291210 291744 291790 291809 31 Journal of Molecular Catalysis A: Chemical JOURNALMOLECULARCATALYSISACHEMICAL 2016-09-15 2016-09-15 2016-12-10 2016-12-10 2019-11-05T09:55:35 1-s2.0-S1381116916303788 S1381-1169(16)30378-8 S1381116916303788 10.1016/j.molcata.2016.09.006 S300 S300.1 FULL-TEXT 1-s2.0-S1381116916X00131 2024-08-28T07:41:59.860803Z 0 0 20170101 20170131 2017 2016-09-15T15:53:00.529001Z absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids confeditor contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb vol volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast grantsponsor grantsponsorid highlightsabst primabst ref specialabst 1381-1169 13811169 true 426 426 PB Volume 426, Part B 38 572 585 572 585 201701 January 2017 2017-01-01 2017-01-31 2017 C–H Functionalization in Modern Molecular Catalysis Alexander Kirillov Dalmo Mandelli article fla © 2016 Elsevier B.V. All rights reserved. CLICKBINOLPHOSPHORICACIDCATALYSTSININTRAMOLECULARENANTIOSELECTIVEOXIDATIVECHBONDFUNCTIONALIZATION STOCKERL S 1 Introduction 2 Experimental 2.1 General information 2.2 Synthesis of PA catalysts 2.2.1 Synthesis of alkynes 2.2.1.1 2,4,6‐Triisopropylbenzaldehyde [18] 2.2.1.2 2,4,6‐Triisopropylphenyl acetylene [19] 2.2.1.3 1‐((3r,5r,7r)‐Adamantan‐1‐yl)ethan‐1‐one [20] 2.2.1.4 (3r,5r,7r)‐1‐Ethynyladamantane [21] 2.2.1.5 4‐Bromo‐2,6‐diisopropylaniline [22] 2.2.1.6 5‐Bromo‐2‐iodo‐1,3‐diisopropylbenzene [23] 2.2.1.7 ((4‐Bromo‐2,6‐diisopropylphenyl)ethynyl)trimethylsilane [23] 2.2.1.8 5‐Bromo‐2‐ethynyl‐1,3‐diisopropylbenzene [23] 2.3 Introduction of the side-chain 2.3.1 (S)‐6,6′‐Dibromo‐[1,1′‐binaphthalene]‐2,2′‐diol (6-Br-BINOL) [24] 2.3.2 (S)‐6,6′‐Dibromo‐2,2′‐bis(methoxymethoxy)‐1,1′‐binaphthalene (7) [25] 2.4 General procedure A: Grignard reaction 2.4.1 (S)‐2,2′‐Bis(methoxymethoxy)‐6,6′‐dioctyl‐1,1′‐binaphthalene (8) [13] 2.4.2 (S)‐2,2′‐Bis(methoxymethoxy)‐6,6′‐didodecyl‐1,1′‐binaphthalene (9) [26] 2.4.3 (S)‐2,2′‐Bis(methoxymethoxy)‐6,6′‐dioctadecyl‐1,1′‐binaphthalene (10) 2.5 General procedure B: synthesis of diazido‐MOM‐BINOLs [15a] 2.5.1 (S)‐3,3′‐Diazido‐2,2′‐bis(methoxymethoxy)‐1,1′‐binaphthalene (4) [15a] 2.5.2 (S)‐3,3′‐Diazido‐2,2′‐bis(methoxymethoxy)‐6,6′‐dioctyl‐1,1′‐binaphthalene (11) 2.5.3 ,3′‐Diazido‐2,2′‐bis(methoxymethoxy)‐6,6′‐didodecyl‐1,1′‐binaphthalene (12) 2.5.4 3,3′‐Diazido‐2,2′‐bis(methoxymethoxy)‐6,6′‐dioctadecyl‐1,1′‐binaphthalene (13) 2.6 General procedure C: copper‐catalyzed cycloaddition of azides with alkynes (CuAAC) 2.6.1 (S)‐1,1′‐(2,2′‐Bis(methoxymethoxy)‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4‐phenyl‐1H‐1,2,3-triazole) (5a) [15a] 2.6.2 (S)‐1,1′‐(2,2′‐Bis(methoxymethoxy)‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4‐mesityl‐1H‐1,2,3-triazole) (5b) [15a] 2.6.3 (S)‐1,1′‐(2,2′‐Bis(methoxymethoxy)‐6,6′‐dioctyl‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4-mesityl-1H- 1,2,3‐triazole) (5c) 2.6.4 (S)‐1,1′‐(2,2′‐Bis(methoxymethoxy)‐6,6′‐dioctyl‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4-(2,4,6‐triiso-propylphenyl)‐1H‐1,2,3‐triazole) (5d) 2.6.5 (S)‐1,1′‐(2,2′‐Bis(methoxymethoxy)‐6,6′‐dioctyl‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4-(adaman-tyl)‐1H‐1,2,3‐triazole) (5e) 2.6.6 (S)‐1,1′‐2,2′‐Bis((methoxymethoxy)‐6,6′‐dioctyl‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4‐(4‐bromo-2,6‐diisopropylphenyl)‐1H‐1,2,3‐triazole) (5f) 2.6.7 (S)‐1,1′‐2,2′‐Bis(methoxymethoxy)‐(6,6′‐didodecyl‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4-mesityl‐1H‐1,2,3‐triazole) (5g) 2.6.8 (S)‐1,1′‐(2,2′‐Bis(methoxymethoxy)‐6,6′‐dioctadecyl‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4‐mesityl‐1H‐1,2,3‐triazole) (5h) 2.7 General procedure D: MOM‐deprotection of BINOL derivatives 2.7.1 (S)‐3,3′‐Bis(4‐phenyl‐1H‐1,2,3‐triazol‐1‐yl)‐[1,1′‐binaphthalene]‐2,2′‐diol (6a) [15a] 2.7.2 (S)‐3,3′‐Bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐[1,1′‐binaphthalene]‐2,2′‐diol (6b) [15a] 2.7.3 (S)‐3,3′‐Bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐6,6′‐dioctyl‐[1,1′‐binaphthalene]‐2,2′‐diol (6c) 2.7.4 (S)‐6,6′‐Dioctyl‐3,3′‐bis(4‐(2,4,6‐triisopropylphenyl)‐1H‐1,2,3‐triazol‐1‐yl)‐[1,1′-binaphthalene]- 2,2′‐diol (6d) 2.7.5 (S)‐6,6′‐dioctyl‐3,3′‐bis(4‐(adamantyl)‐1H‐1,2,3‐triazol‐1‐yl)‐[1,1′-binaphthalene]‐2,2′‐diol (6e) 2.7.6 (S)‐3,3′‐Bis(4‐(4‐bromo‐2,6‐diisopropylphenyl)‐1H‐1,2,3‐triazol‐1‐yl)‐6,6′‐dioctyl‐[1,1′-binaphthalene]‐2,2′‐diol (6f) 2.7.7 (S)‐3,3′‐Bis(4‐mesityl‐1H‐1,2,3-triazol‐1‐yl)‐6,6′‐didodecyl‐[1,1′‐binaphthalene]‐2,2′‐diol (6g) 2.7.8 (S)‐3,3′‐Bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐6,6′‐dioctadecyl‐[1,1′‐binaphthalene]‐2,2′-diol (6h) 2.8 General procedure E: Synthesis of phosphoric acids [13] 2.8.1 (S)‐4‐Hydroxy‐2,6‐bis(4‐phenyl‐1H‐1,2,3‐triazol‐1‐yl)dinaphtho[2,1‐d:1′,2′‐f-1,3,2]dioxaphos-phepine 4‐oxide (1a) 2.8.2 (S)‐4‐Hydroxy‐2,6‐bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)dinaphtho[2,1‐d:1′,2′‐f-1,3,2]dioxaphos-phepine 4‐oxide (1b) 2.8.3 (4R,11bS)‐4‐Hydroxy‐2,6‐bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐9,14‐dioctyldinaphtho[2,1‐d:1′,2′‐f-1,3,2]dioxaphosphepine 4‐oxide (1c) 2.8.4 (4R,11bS)‐4‐hydroxy‐9,14‐dioctyl‐2,6‐bis(4‐(2,4,6‐triisopropylphenyl)‐1H‐1,2,3‐triazol‐1-yl) dinaphtho[2‐d:1′,2′‐f][2,1‐d:1′,2′‐f][1,3,2]dioxaphosphepine 4‐oxide (1d) 2.8.5 (4R,11bS)‐4‐hydroxy‐9,14‐dioctyl‐2,6‐bis(4‐(adamantyl)‐1H‐1,2,3‐triazol‐1-yl)dinaphtho [2‐d:1′,2′‐f][2,1‐d:1′,2′‐f][1,3,2]dioxaphosphepine 4‐oxide (1e) 2.8.6 (4R,11bS)‐2,6‐Bis(4‐(4‐bromo‐2,6‐diisopropylphenyl)‐1H‐1,2,3‐triazol‐1‐yl)‐4‐hydroxy-9,14‐dioctyldinaphtho[2‐d:1′,2′‐f][2,1‐d:1′,2′‐f][1,3,2]dioxaphosphepine 4‐oxide (1f) 2.8.7 (4R,11bS)‐2,6‐Bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐4‐hydroxy–9,14‐didodecyldinaphtho [2‐d:1′,2′‐f][2,1‐d:1′,2′‐f][1,3,2]dioxaphosphepine 4‐oxide (1g) 2.8.8 (4R,11bS)‐2,6‐Bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐4‐hydroxy‐9,14‐dioctadecyldinaphtho [2‐d:1′,2′‐f][2,1‐d:1′,2′‐f][1,3,2]dioxaphosphepine 4‐oxide (1h) 2.8.9 N‐((4S,11bS)‐2,6‐Bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐9,14‐dioctyl‐4‐oxidodinaphtho[2‐d:1′,2′‐f][2,1‐d:1′,2′‐f] [1,3,2]dioxaphosphepin‐4‐yl)‐1,1,1‐trifluoromethanesulfonamide (1c#) [27] 2.9 General procedure for the catalytic reaction 2.9.1 5‐Benzyl‐4b,5,12,13‐tetrahydro‐6H‐isoquinolino[2,1‐a]quinazolin‐6‐one (3a) [13,16c] 2.9.2 5-(4-Chlorobenzyl)-4b,5,12,13-tetrahydro-6H-isoquinolino[2,1-a]quinazolin-6-one (3b) 2.9.3 5-(3,4-Dimethoxybenzyl)-4b,5,12,13-tetrahydro-6H-isoquinolino[2,1-a]quinazolin-6-one (3c) [16c] 2.9.4 5-((S)-1-Phenylethyl)-4b,5,12,13-tetrahydro-6H-isoquinolino[2,1-a]quinazolin-6-one (3d) 2.9.5 4b,5,12,13-Tetrahydro-6H-isoquinolino[2,1-a]quinazolin-6-one (3e) [16a,b] 2.9.6 5-Cyclohexyl-4b,5,12,13-tetrahydro-6H-isoquinolino[2,1-a]quinazolin-6-one (3f) [13,16c] 2.9.7 5-(2-Chlorophenyl)-4b,5,12,13-tetrahydro-6H-isoquinolino[2,1-a]quinazolin-6-one (3g) [13] 2.9.8 4b,13-Dihydro-6H,12H-benzo[4,5][1,3]oxazino[2,3-a]isoquinolin-6-one (3h) [16a,c] 2.9.9 6,6-Dimethyl-4b,13-dihydro-6H,12H-benzo[4,5][1,3]oxazino[2,3-a]isoquinoline (3i) 2.9.10 6,7,11b,12-Tetrahydro-13H-isoquinolino[2,1-a]quinolin-13-one (3j) [16] 3 Results and discussion 4 Conclusions Acknowledgements Appendix A Supplementary data References LI 2004 11810 Z LI 2005 3672 Z DYKER 2005 G HANDBOOKCHTRANSFORMATIONS YU 2010 J TOPICSINCURRENTCHEMISTRY SCHEUERMANN 2010 436 C KLUSSMANN 2011 353 M YEUNG 2011 1215 C LIU 2011 1780 C ROHLMANN 2013 6 R GIRARD 2014 74 S NARAYAN 2015 14678 R DAVIES 2016 343 H HARTWIG 2016 281 J QIN 2014 551 Y LIU 2015 288 W BOESS 2012 5317 E RICHTER 2010 4460 H RICHTER 2011 6066 H RICHTER 2011 11622 H RICHTER 2012 8656 H ROHLMANN 2013 6050 R STOPKA 2015 5049 T BOBBITT 1988 509 J BOBBITT 2009 J OXOAMMONIUMNITROXIDECATALYZEDOXIDATIONSALCOHOLSINORGREACTIONS STOPKA 2013 1602 T MERCADANTE 2013 666 M HAMLIN 2015 8150 T WETZ 2011 11511 S YAN 2014 60075 C SUN 2015 1684 S LI 2004 4997 Z QIN 2014 551 Y ZHENG 2014 6173 C LIU 2015 288 W SASAMOTO 2006 14010 N BASLEAND 2008 3661 O ZHANG 2011 10429 G CAO 2013 3470 W YU 2013 2006 J PEREPICHKA 2015 447 I ZHAO 2015 3703 Y STOCKERL 2016 277 S NICOLAOU 2009 2086 K CONRAD 2009 11640 J BENFATTI 2009 5919 F HO 2010 4436 X ZHANG 2011 5212 B ZHANG 2012 3649 J MENG 2014 553 Z MA 2014 5358 Y LIU 2015 2396 X MAHLAU 2013 518 M BRAK 2013 534 K BECKENDORF 2012 926 S AKIYAMA 2007 5744 T TERADA 2010 1929 M PHIPPS 2012 603 R PARMAR 2014 9047 D NEEL 2013 14044 A MILO 2015 737 A BERGONZINI 2014 112 G BECKENDORF 2012 2162 S RECSEI 2012 464 C LIU 2006 2149 B TO 2013 5654 W HUO 2014 9860 C LIU 2016 3372 Y GOTTLIEB 1997 7512 H CASARINI 2008 2811 D BOUFFARD 2011 2617 J CHEN 2014 627 Y BUSCH 2009 8251 M BASAURIMOLINA 2015 15676 M FUJIHARA 2011 9699 T SCHUBERT 2012 6851 C ISHITANI 2000 8180 H ISHIKAWA 2015 8988 D NAKASHIMA 2006 9626 D STOCKERLX2017X572 STOCKERLX2017X572X585 STOCKERLX2017X572XS STOCKERLX2017X572X585XS 2018-12-10T00:00:00.000Z http://creativecommons.org/licenses/by-nc-nd/4.0/ © 2016 Elsevier B.V. All rights reserved. 2019-03-20T05:44:58.397Z http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp S1381116916303788 Deutsche Forschungsgemeinschaft Deutsche Forschungsgemeinschaft http://data.elsevier.com/vocabulary/SciValFunders/501100001659 http://sws.geonames.org/2921044/ The Deutsche Forschungsgemeinschaft (DFG) is gratefully acknowledged for financial support. D. G. thanks the Deutscher Akademischer Austauschdienst (DAAD) and the University of Regensburg for an iPur PhD-exchangefellowship. Appendix A item S1381-1169(16)30378-8 S1381116916303788 1-s2.0-S1381116916303788 10.1016/j.molcata.2016.09.006 271358 2024-08-28T07:41:59.860803Z 2017-01-01 2017-01-31 1-s2.0-S1381116916303788-mainext.pdf https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:102XZCGQ4HD/MAIN/application/pdf/b1770e47a882b8bc82bfbf3c0fda798b/mainext.pdf mainext.pdf pdf true 2394638 MAIN 16 1-s2.0-S1381116916303788-main_1.png https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/PREVIEW/image/png/fe5894cf9753c2ebe3fabad83cd145e9/main_1.png main_1.png png 58892 849 656 IMAGE-WEB-PDF 1 1-s2.0-S1381116916303788-main.pdf https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/MAIN/application/pdf/a3ee69c15351f66d2824322d5be9442d/main.pdf main.pdf pdf true 1974400 MAIN 14 1-s2.0-S1381116916303788-main_1.png https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/PREVIEW/image/png/fe5894cf9753c2ebe3fabad83cd145e9/main_1.png main_1.png png 58892 849 656 IMAGE-WEB-PDF 1 1-s2.0-S1381116916303788-fx1.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/fx1/THUMBNAIL/image/gif/2514dc79529813d8db938170eb7662b5/fx1.sml fx1 true fx1.sml sml 4523 164 201 IMAGE-THUMBNAIL 1-s2.0-S1381116916303788-fx2.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/fx2/THUMBNAIL/image/gif/c7ff2ca6fffa485cb026fe9b6bdaf95a/fx2.sml fx2 fx2.sml sml 3741 164 201 IMAGE-THUMBNAIL 1-s2.0-S1381116916303788-gr1.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/gr1/THUMBNAIL/image/gif/21577eeba9672dacd2a2c57f61f1a845/gr1.sml gr1 gr1.sml sml 6287 164 172 IMAGE-THUMBNAIL 1-s2.0-S1381116916303788-gr2.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/gr2/THUMBNAIL/image/gif/845568402ac70810b6d245480c1e3c1c/gr2.sml gr2 gr2.sml sml 7743 126 219 IMAGE-THUMBNAIL 1-s2.0-S1381116916303788-sc1.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/sc1/THUMBNAIL/image/gif/9be97d7edd8693801c10cb99ab2241e7/sc1.sml sc1 sc1.sml sml 6637 126 219 IMAGE-THUMBNAIL 1-s2.0-S1381116916303788-sc2.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/sc2/THUMBNAIL/image/gif/c3d90f65c0e6cae18dd4a65d154482cf/sc2.sml sc2 sc2.sml sml 9247 161 219 IMAGE-THUMBNAIL 1-s2.0-S1381116916303788-sc3.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/sc3/THUMBNAIL/image/gif/142196722801cf50ee6205cea465ec96/sc3.sml sc3 sc3.sml sml 5765 164 141 IMAGE-THUMBNAIL 1-s2.0-S1381116916303788-sc4.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/sc4/THUMBNAIL/image/gif/be85180c2733cc541c7d3f099ea249ca/sc4.sml sc4 sc4.sml sml 4554 164 166 IMAGE-THUMBNAIL 1-s2.0-S1381116916303788-fx1.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/fx1/DOWNSAMPLED/image/jpeg/6c196cb2816bfdaa20471b01a6bf0cfb/fx1.jpg fx1 true fx1.jpg jpg 10070 245 301 IMAGE-DOWNSAMPLED 1-s2.0-S1381116916303788-fx2.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/fx2/DOWNSAMPLED/image/jpeg/07a5b45b6e0ae7e06aa2d7c05ffb08ff/fx2.jpg fx2 fx2.jpg jpg 9281 245 301 IMAGE-DOWNSAMPLED 1-s2.0-S1381116916303788-gr1.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/gr1/DOWNSAMPLED/image/jpeg/cb454dd17d6c390abee2b4ed5a6094c3/gr1.jpg gr1 gr1.jpg jpg 26505 304 320 IMAGE-DOWNSAMPLED 1-s2.0-S1381116916303788-gr2.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/gr2/DOWNSAMPLED/image/jpeg/8dac1220dd98a69e8aa70fce5661994c/gr2.jpg gr2 gr2.jpg jpg 40996 280 489 IMAGE-DOWNSAMPLED 1-s2.0-S1381116916303788-sc1.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/sc1/DOWNSAMPLED/image/jpeg/40c81dee2946d00f2b0face183390cd8/sc1.jpg sc1 sc1.jpg jpg 39303 282 489 IMAGE-DOWNSAMPLED 1-s2.0-S1381116916303788-sc2.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/sc2/DOWNSAMPLED/image/jpeg/a5e94c5718f2c119a61d19c626a7758f/sc2.jpg sc2 sc2.jpg jpg 83947 497 678 IMAGE-DOWNSAMPLED 1-s2.0-S1381116916303788-sc3.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/sc3/DOWNSAMPLED/image/jpeg/341609e96ede8a827886e282a0961845/sc3.jpg sc3 sc3.jpg jpg 62886 567 489 IMAGE-DOWNSAMPLED 1-s2.0-S1381116916303788-sc4.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/sc4/DOWNSAMPLED/image/jpeg/7d3b5246ef55570b4d3c749ac79ea46d/sc4.jpg sc4 sc4.jpg jpg 46117 483 489 IMAGE-DOWNSAMPLED 1-s2.0-S1381116916303788-fx1_lrg.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/fx1/HIGHRES/image/jpeg/ac330610e4fba0ca6cd22fa61503f38c/fx1_lrg.jpg fx1 true fx1_lrg.jpg jpg 83703 1085 1333 IMAGE-HIGH-RES 1-s2.0-S1381116916303788-fx2_lrg.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/fx2/HIGHRES/image/jpeg/1e1509511dd814455a27517aa7e9d8eb/fx2_lrg.jpg fx2 fx2_lrg.jpg jpg 63859 1085 1333 IMAGE-HIGH-RES 1-s2.0-S1381116916303788-gr1_lrg.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/gr1/HIGHRES/image/jpeg/3ed6b657c52f23d458e8012184477ba6/gr1_lrg.jpg gr1 gr1_lrg.jpg jpg 186602 1347 1417 IMAGE-HIGH-RES 1-s2.0-S1381116916303788-gr2_lrg.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/gr2/HIGHRES/image/jpeg/d67a6ef0e7f1abf97cd723352982cb1a/gr2_lrg.jpg gr2 gr2_lrg.jpg jpg 282416 1243 2167 IMAGE-HIGH-RES 1-s2.0-S1381116916303788-sc1_lrg.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/sc1/HIGHRES/image/jpeg/e92d52e2f58674cb524b3f3a4bcd86c0/sc1_lrg.jpg sc1 sc1_lrg.jpg jpg 269428 1250 2167 IMAGE-HIGH-RES 1-s2.0-S1381116916303788-sc2_lrg.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/sc2/HIGHRES/image/jpeg/ea8aa41acc4a1ebe131ced5f83c68ad4/sc2_lrg.jpg sc2 sc2_lrg.jpg jpg 685141 2201 3000 IMAGE-HIGH-RES 1-s2.0-S1381116916303788-sc3_lrg.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/sc3/HIGHRES/image/jpeg/1ff32564abb1be86184c72eb9a4c9389/sc3_lrg.jpg sc3 sc3_lrg.jpg jpg 428766 2514 2167 IMAGE-HIGH-RES 1-s2.0-S1381116916303788-sc4_lrg.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/sc4/HIGHRES/image/jpeg/9df9e2a0a35c594c67f6a70d89b66cea/sc4_lrg.jpg sc4 sc4_lrg.jpg jpg 320268 2139 2167 IMAGE-HIGH-RES 1-s2.0-S1381116916303788-mmc1.pdf https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116916303788/mmc1/MAIN/application/pdf/dd77beb3d11a97d3d74633a7364c7b60/mmc1.pdf mmc1 mmc1.pdf pdf false 9506577 APPLICATION MOLCAA 10030 S1381-1169(16)30378-8 10.1016/j.molcata.2016.09.006 Elsevier B.V. Scheme 1 Concept and examples of asymmetric counter-anion organocatalysis in CH bond functionalization. Scheme 1 Scheme 2 Synthesis of the new triazole-based PA-catalysts. Scheme 2 Scheme 3 Reaction with substituted THIQ 2. a Conditions: i) 2 (1 equiv.), AcNHT+BF4 − (2.2 equiv.), 1c (10 mol%) and Na3PO4 (2.4 equiv.) were stirred in dry Et2O at r.t. for 24h. b Isolated yield. c Enantiomeric ratios determined by chiral HPLC (e.r. values after a single recrystallization from CH2Cl2/hexane in brackets). d 1.0mmol reaction scale. e The enantiomers could not be separated by chiral HPLC using hexanes/iPrOH mixtures as eluent. Scheme 3 Scheme 4 Plausible mechanism and stoichiometric anion-exchange study. Scheme 4 Fig. 1 Click-BINOL derivatives in asymmetric catalysis. Fig. 1 Fig. 2 Comparison of PA-catalysts in the model intramolecular CH functionalization reaction. Fig. 2 Table 1 Optimization of the reaction with 2a a . Table 1 entry oxidant catalyst base solvent yield (%) b e.r. c 1 AcNHT+BF4 − – Na3PO4 toluene 66 – 2 AcNHT+BF4 − 1a Na3PO4 toluene 65 41:59 3 AcNHT+BF4 − 1b Na3PO4 toluene 89 60:40 4 AcNHT+BF4 − 1c Na3PO4 toluene 99 66:34 5 AcNHT+BF4 − 1d Na3PO4 toluene 99 66:34 6 AcNHT+BF4 − 1e Na3PO4 toluene 99 64:36 7 AcNHT+BF4 − 1c Na3PO4 p-xylene 74 70:30 8 AcNHT+BF4 − 1c Na3PO4 MTBE 99 74:26 9 AcNHT+BF4 − 1c Na3PO4 Et2O 99 78:22 10 AcNHT+BF4 − 1c# Na3PO4 Et2O 73 67:33 11 AcNHT+BF4 − 1d Na3PO4 Et2O 95 70:30 12 AcNHT+BF4 − 1e Na3PO4 Et2O 93 74:26 13 AcNHT+BF4 − 1f Na3PO4 Et2O 84 46:54 14 AcNHT+BF4 − 1g Na3PO4 Et2O 80 68:32 15 AcNHT+BF4 − 1h Na3PO4 Et2O 87 74:26 16 AcNHT+BF4 − 1c K3PO4 Et2O 77 66:34 17 AcNHT+BF4 − 1c K2CO3 Et2O 60 75:25 18 AcNHT+ClO4 − 1c Na3PO4 Et2O 99 63:37 19 T+BF4 − 1c Na3PO4 Et2O 88 66:34 20 Ph3C+BF4 − 1c Na3PO4 Et2O 86 54:46 21 AcNHT+BF4 − 1c Na3PO4 Et2O d 78 77:23 22 AcNHT+BF4 − 1c Na3PO4 Et2O e 92 56:44 23 AcNHT+BF4 − 1c f Na3PO4 Et2O 80 75:25 24 AcNHT+BF4 − 1c g Na3PO4 Et2O 83 73:27 a Conditions: i) 2a (1 equiv.), oxidant (2.2 equiv.), PA-catalyst 1 (10 mol%) and base (2.4 equiv.) were stirred in the appropriate dry solvent at r.t. for 24h. b Isolated yield. c Enantiomeric ratios determined by chiral HPLC. d Reaction at −20°C. e Reaction at −40°C. f 5mol% of catalyst was used. g 2.5mol% of catalyst was used. Click-binol-phosphoric acid catalysts in intramolecular enantioselective oxidative CH-bond functionalization Sebastian Stockerl a Daniel Gutiérrez a Olga García Mancheño a b ⁎ a Institute for Organic Chemistry, University of Regensburg, 93053 Regensburg, Germany Institute for Organic Chemistry University of Regensburg Regensburg 93053 Germany b Straubing Center of Science for Renewable Resources, 94315 Straubing, Germany Straubing Center of Science for Renewable Resources Straubing 94315 Germany ⁎ Corresponding author at: Institute for Organic Chemistry, University of Regensburg, 93053 Regensburg, Germany. Institute for Organic Chemistry University of Regensburg Regensburg 93053 Germany Graphical abstract Counteranion-catalysis represents an appealing but challenging approach for the development of enantioselective oxidative CH bond functionalization reactions. In this work, a new family of 3,3′-triazolyl BINOL-derived phosphoric acids was synthesized and employed in the intramolecular asymmetric CH bond functionalization of N-aryl substituted tetrahydroisoquinolines. As previously reported with related structures, the presence of the triazole groups on the catalysts was key to attain enantioselectivity. Our study also shows the importance of choosing the appropriate regioisomeric triazole groups at the BINOL backbone to achieve a more efficient chirality transfer. Moderate enantiomeric ratios were obtained with the N-benzamide substrates, whereas the change of the nature of the nucleophile fragment was translated to a dramatic loss of the enantioselectivity. Therefore, it can be foreseen that there is a need for designing further superior catalyst structures to develop future counter-anion organocatalyzed asymmetric CH bond functionalization reactions. Keywords CH functionalization Oxidation Organocatalysis Enantioselective Heterocycles 1 Introduction In the last few years, selective CH bond functionalization has attracted great interest, such as the cross-dehydrogenative coupling (CDC) coined by Li [1], since it offers not only more straightforward approaches but also new possibilities in synthetic chemistry [2,3]. The growing demand on innovative and simple direct CH bond transformations has led to important breakthroughs in the chemistry of oxidative C(sp3)H functionalization [2–4]. Our research group has also contributed to this field by developing novel, mild oxidative reactions for the synthesis of valuable (bioactive)heterocycles [5]. Thus, we have recently introduced the use of TEMPO oxoammonium salts (T+X−) [6,7] as alternative mild and efficient oxidants for CC bond forming reactions of C(sp3)H bonds, allowing in some cases to overcome certain substrate or product incompatibilities with the classically used oxidants. Additionally, recent efforts towards the development of enantioselective C(sp3)H bond functionalization have been made [8]. Besides the initially explored metal-catalyzed reactions [9], organocatalysis represents a powerful approach [10]. Most of the reported examples rely on covalent amino-catalysis, which limit its applicability to carbonyl compounds. Considering that the key intermediate in this type of transformations is an ionic species such as an iminium ion, counteranion organocatalysis has recently been embraced (Scheme 1 ) [11]. The first intramolecular CH functionalization approach was based on the use of chiral phosphoric acids (PA) [12] to generate in situ the active phosphate catalyst responsible for the formation of a chiral close ion-pair and the enantioselectivity control [13]. Shortly after, the combination of metal-photocatalysis and a chiral thiourea as anion-binding catalyst was utilized for the intermolecular functionalization of N-aryl tetrahydroisoquinolines (THIQs) [14]. Despite of the tremendous interest that counter - anion catalysis is currently evoking in the synthetic scientific community [11], a still limited number of effective catalyst motifs is available. Aiming at providing alternative novel structures, we recently developed a modular strategy to introduce 1,2,3-triazole moieties into BINOL derivatives (Click-BINOLs), which were employed as ligands in asymmetric Lewis acid metal catalysis (Fig. 1 , bottom) [15]. Later on, the group of Toste [13] reported the performance of phosphoric acids derived from the regioisomeric 3,3′-triazolyl BINOLs (Fig. 1, top-right) as superior organocatalysts in the enantioselective CH bond functionalization of tetrahydroisoquinoline-N-benzamides as shown in Scheme 1 [16]. As part of our ongoing research program devoted to the development of asymmetric CH bond functionalization reactions, we herein described our latest results in the area of counteranion-catalysis using a new family of chiral Click-BINOL-based phosphates (Fig. 1, top-left). 2 Experimental 2.1 General information 1H and 13C NMR spectra were recorded in CDCl3 (reference signals [17]: 1H=7.26ppm, 13C=77.16ppm, CDCl3) on a Bruker ARX-300 and a Varian AV-300, 400 or 600MHz. Chemical shifts (δ) are given in ppm and spin-spin coupling constants (J) are given in Hz. Analytical thin layer chromatography was performed using silica gel 60F254 and a solution of KMnO4 or phosphomolybdic acid served as staining agent. Column chromatography was performed on silica gel 60 (0.040–0.063mm). Exact masses (HRMS) were recorded on an Agilent Q-TOF 6540 UHD spectrometer (samples in CH3OH as solvent) using electrospray (ES) or chemical (CI) ionization techniques. Chiral High Pressure Liquid Chromatography (HPLC) analyses were performed on an Agilent 1200 series instrument. 2.2 Synthesis of PA catalysts 2.2.1 Synthesis of alkynes 2.2.1.1 2,4,6‐Triisopropylbenzaldehyde [18] A stirring solution of 1-bromo-2,4,6‐triisopropylbenzene (5.25ml, 20.0mmol, 1.0 eq.) in dry THF (40ml) was cooled to −78°C. n‐BuLi (1.6M in hexane; 13.8ml, 22.0mmol, 1.1 eq.) was added over 20min. After stirring for additional 20 min, dry DMF (1.8ml, 22.0mmol, 1.1 eq.) was added slowly. The reaction mixture was stirred 15min at −78°C, allowed to warm to −10°C and quenched with H2O (20ml). The aqueous layer was extracted with ether (3×20ml) and dried over Na2SO4. Purification by column chromatography using PE/EtOAc (10:1) as eluent gave the title compound (3.6g, 15.6mmol, 78%) as a colorless oil. R f =0.66 (10:1) (SiO2, PE/EtOAc). 1H‐NMR (300 MHz, CDCl3) δ[ppm]: 10.66 (s, 1H), 7.11 (s, 2H), 3.60 (sept., J =6.8 Hz, 2H), 2.92 (sept., J =6.9 Hz, 1H), 1.27 (d, J =6.9 Hz, 6H), 1.26 (d, J =6.9Hz, 6H). The analytical data are in accordance with the literature. 2.2.1.2 2,4,6‐Triisopropylphenyl acetylene [19] A stirring, degassed solution of triphenylphosphine (15.9g, 60.0mmol, 4.0 eq.) and carbon tetrabromide (10.2g, 30.0mmol, 2.0 eq.) in dry dichloromethane (200ml) was cooled to 0°C and 2,4,6-triisopropylphenylbenzaldehyde (3.6g, 15.0mmol, 1.0 eq.) was added. The reaction mixture was allowed to warm to rt overnight. The solids were filtered off and the solvent was removed under reduced pressure. PE (400ml) was added and after trituration the solution was filtered over a silica plug using PE as eluent. The solvent was removed under reduced pressure and the crude intermediate was dissolved in dry THF (50ml). The reaction mixture was cooled to −78°C, n-BuLi (1.6 M in hexane; 11.8ml, 18.75mmol, 1.25 eq.) was added dropwise. After 1h, the reaction mixture was allowed to warm to rt and quenched with sat. aq. NH4Cl (30 ml). The aqueous layer was extracted with PE (3×40ml). The solvent was removed under reduced pressure and the crude alkyne was filtered over a silica plug using PE as eluent. A small crystal of hydrochinone was added and the solvent was removed to give the title compound (2.5g, 10.9mmol, 73%) as a pale purple oil. 1H‐NMR (300MHz, CDCl3) δ[ppm]: 6.98 (s, 2H), 3.54 (sept., J =6.9 Hz, 2H), 3.42 (s, 1H), 2.89 (sept., J =6.9 Hz, 1H), 1.26 (d, J =6.8 Hz, 6H), 1.25 (d, J =6.9 Hz, 6H). The analytical data are in accordance with the literature. 2.2.1.3 1‐((3r,5r,7r)‐Adamantan‐1‐yl)ethan‐1‐one [20] A stirring solution of adamantyl carboxylic acid (1.8g, 10.0mmol, 1.0 eq.) in thionyl chloride (4.0ml, 55.1mmol, 5.51 eq.) was refluxed for 4h. The excess of thionyl chloride was removed under reduced pressure to give the 1-adamantanecarbonyl chloride. Diethylmalonate (2.5g, 2.4ml, 15.5mmol, 1.55 eq.) in PE (5ml) was added dropwise to a stirring solution of sodium (0.35g, 15.5mmol, 1.55 eq.) in PE (10ml). After complete consumption of sodium, carbonyl chloride in PE (5 ml) was added slowly and the resulting reaction mixture was stirred overnight at rt. Distilled water (20ml) was added, the organic layer was separated and concentrated under vacuum. Acetic acid (8ml), water (2.4ml) and sulfuric acid (0.8ml) were added and the reaction mixture was refluxed for 6h. The solution was poured into ice water (60ml) for crystallization. The resulting crystals were filtered off and dried under vacuum to give the title compound (0.8g, 4.8mmol, 48%) as white needles. 1H‐NMR (300MHz, CDCl3) δ[ppm]: 2.07 (s, 3H), 2.04–2.01 (m, 3-H), 1.78 (d, J =2.8 Hz, 6H), 1.73–1.61 (m, 6H). The analytical data are in accordance with the literature. 2.2.1.4 (3r,5r,7r)‐1‐Ethynyladamantane [21] A stirring solution of diisopropyl amine (0.8ml, 5.7mmol, 1.19 eq.) in dry THF (7ml) was cooled to −78°C followed by dropwise addition of n-BuLi (1.6M in hexane; 3.25ml, 5.2mmol, 1.08mmol) and was stirred for 1h. Adamantyl methyl ketone (0.85g, 4.8mmol, 1.0 eq.) in dry THF (3ml) was added at −78°C to the LDA solution. After 1h, chloro diethyl phosphate (0.86g, 5.0mmol, 1.05 eq.) was added dropwise. The resulting reaction mixture was allowed to warm to rt and stirred for 3h. A second LDA solution was prepared as already described from diisopropyl amine (1.4ml, 9.5mmol, 1.98 eq.) in THF (15ml) and n-BuLi (1.6M in hexane; 6.4ml, 10.3ml, 2.15 eq.) at −78°C. After 3h the reaction mixture was added to the second LDA solution at −78°C, allowed to warm to rt and stirred overnight. The reaction mixture was quenched with H2O (20ml) and the aqueous layer was extracted with PE (4×15ml). The combined organic layers were washed with ice-cold 1M HCl (2×15ml), sat. aq. NaHCO3 (2×20ml) (pH should be 9) and dried over Na2SO4. The solution was filtered over Celite and the solvent was removed under reduced pressure. Purification by filtration over a silica plug using PE as eluent gave the title compound (0.44g, 2.8mmol, 58%) as a colorless oil. 1H‐NMR (300MHz, CDCl3) δ[ppm]: 2.10 (s, 1H), 1.99–1.93 (m, 3H), 1.89 (d, J =2.8 Hz, 6H), 1.69 (t, J =3.1 Hz, 6H). The analytical data are in accordance with the literature. 2.2.1.5 4‐Bromo‐2,6‐diisopropylaniline [22] A solution of Br2 (2.1ml, 41.0mmol, 1.05 eq.) in CH2Cl2/MeOH (100ml, 1:1v/v) was added to a stirring solution of 2,6-diisopropylaniline (7.4ml, 39.0mmol, 1.0 eq.) in CH2Cl2/MeOH (200ml, 1:1v/v) at r.t. over 2h. The orange-red solution was stirred for 1day. The solvents were evaporated and the resultant pink solid was washed with PE and further recristallized from CH2Cl2/PE to give the title compound as light orange-red solid (7.8g, 28.1mmol, 72%). 1H‐NMR (300MHz, CDCl3) δ[ppm]: 10.08 (s, 2H), 7.36 (s, 2H), 3.80–3.62 (m, 2H), 1.29 (d, J =6.7 Hz, 12H). The analytical data are in accordance with the literature. 2.2.1.6 5‐Bromo‐2‐iodo‐1,3‐diisopropylbenzene [23] To a solution of 4-bromo-3,5-dimethylaniline (8.0g, 40mmol, 1.0 eq.) in aq. H2SO4 (360ml, 6.0M) at −15°C, a solution of NaNO2 (5.6g, 80mmol, 2.0 eq.) in H2O (32ml) was added dropwise over a period of 20min. The resulting mixture was stirred at −15°C for an additional 15min. Then, a solution of KI (16.6g, 100.0mmol, 2.5 eq.) in H2O (320ml) was slowly added in portions to the mixture over a period of 25min. The reaction mixture was stirred at −10°C for 30min, then stirred at 0°C for 4h. After the mixture was stirred overnight at room temperature, the resulting mixture was neutralized by adding Na2CO3. The mixture was subsequently extracted with Et2O (2×200ml). The combined organic layers were washed with H2O (200ml), aq. Na2SO3 (1 M, 2×100ml), aq. NaOH (2.5 M, 2×100ml) and H2O (100ml), dried over Na2SO4 and the solvent was removed under reduced pressure. The residue was purified by column chromatography using PE as eluent, providing the title compound (6.4g, 22.4mmol, 56%) as colorless oil. The analytical data are in accordance with the literature. 2.2.1.7 ((4‐Bromo‐2,6‐diisopropylphenyl)ethynyl)trimethylsilane [23] PdCl2(PPh3)2 (0.13g, 0.19mmol, 1.2mol%), CuI (72mg, 0.38mmol, 2.4mol%) and H2O (0.5ml, 27.0mmol, 1.7 eq.) were added to a solution of 5-bromo-2-iodo-1,3-diisopropylbenzene (5.8g, 15.8mmol, 1.0 eq.) and trimethylsilylacetylene (4.1g, 22.0mmol, 1.4 eq.) in degassed piperidine (30ml) at 0°C under an argon atmosphere. The reaction mixture was stirred at 0°C for 1h and for an additional 2h at r.t. After filtration over Celite, the solvent was removed under reduced pressure. The residue was dissolved in 1M HCl (30ml) and Et2O (30ml). The organic layer was washed with brine (2×20ml), dried over Na2SO4 and the solvent was removed under reduced pressure. The residue was purified by column chromatography using PE as an eluent to give the title compound (2.5g, 7.4mmol, 47%) as colorless oil. 1H‐NMR (300 MHz, CDCl3) δ[ppm]: 7.23 (s, 2H), 3.47 (sept., J =6.8 Hz, 2H), 1.25 (d, J =6.9 Hz, 12H), 0.28 (s, 9H). 13C‐NMR (100MHz, CDCl3) δ[ppm]: 147.9, 127.7, 127.2, 122.1, 104.9, 94.1, 33.5, 22.9, 0.0. HRMS (EI): m/z [M]+. calcd for C17H25BrSi+.: 336.0909; found: 336.0894. 2.2.1.8 5‐Bromo‐2‐ethynyl‐1,3‐diisopropylbenzene [23] K2CO3 (3.0g, 21.0mmol, 2.8 eq.) was added to a solution of ((4-bromo-2,6-diisopropylphenyl) ethynyl)trimethylsilane (2.5g, 7.4mmol, 1.0 eq.) in dry MeOH (25ml) under an argon atmosphere and the mixture was stirred at 40°C for 24h. Sat. aq. NH4Cl solution (100ml) and pentane (100ml) were added to the mixture and the layers were separated. The organic layer was washed with H2O (2×50ml), dried over Na2SO4 and the solvent was removed under reduced pressure. Purification by column chromatography using PE as an eluent gave the title compound (1.5g, 4.7mmol, 64%) as colorless oil. 1H‐NMR (300MHz, CDCl3) δ[ppm]: 7.22 (s, 2H), 3.44 (sept., J =6.8 Hz, 2H), 3.07 (s, 1H), 1.21 (d, J =6.8 Hz, 12H). 13C‐NMR (100 MHz, CDCl3) δ[ppm]: 148.1, 127.9, 127.5, 121.1, 83.6, 77.2, 33.5, 22.9. HRMS (EI): m/z [M]+. calcd for C14H17Br+.: 264.0514; found: 264.0510. 2.3 Introduction of the side-chain 2.3.1 (S)‐6,6′‐Dibromo‐[1,1′‐binaphthalene]‐2,2′‐diol (6-Br-BINOL) [24] (S)-BINOL (7.20g, 25.0mmol, 1.0 eq.) was suspended in CH2Cl2 (250ml) at −78°C. A solution of Br2 (3.9ml, 34.0mmol, 1.4 eq.) in CH2Cl2 (40ml) was added dropwise to the reaction (over 20–30min) and stirred further 15min at −78°C. The mixture was then let to reach r.t. and reacted until full conversion was observed by TLC (aprox. 3h). A sat. aq. solution of Na2S2O3 (50ml) was added and the aqueous layer extracted with EtOAc (3×50ml). The combined organic layers were dried over MgSO4, filtered and the solvent was removed under reduced pressure. Recrystallization from CH2Cl2/pentane gave the title compound as a white solid (10.34g, 23.3mmol, 93%). 1H‐NMR (300 MHz, CDCl3) δ[ppm]: 8.03 (d, J =1.9 Hz, 2H), 7.87 (d, J =9.0 Hz, 2H), 7.45–7.35 (m, m 4H), 6.94 (d, J =9.0Hz, 2H), 5.00 (bs, 2H). 13C‐NMR (75MHz, CDCl3) δ[ppm]: 153.0, 131.9, 130.8, 130.7, 130.6, 130.4, 125.9, 119.0, 118.0, 110.7. The analytical data are in accordance with the literature. 2.3.2 (S)‐6,6′‐Dibromo‐2,2′‐bis(methoxymethoxy)‐1,1′‐binaphthalene (7) [25] A stirring solution of NaH (60 % in mineral oil, 1.5g, 37.5mmol, 2.5 eq.) in a mixture of THF-DMF (2:1, 45 ml) was cooled to 0°C. (S)- 6-Br-BINOL (6.7g, 15.0mmol, 1.0 eq.) in THF (10ml) was added dropwise and the resulting solution was stirred at rt for 1h. Chloro(methoxy)methane (4.2g, 52.5mmol, 3.5 eq.) was added and the reaction mixture was stirred at rt for 4h. The solution was quenched with H2O (50ml) and extracted with EtOAc (3×50ml). The combined organic layers were washed with brine, dried over Na2SO4 and the solvent was removed under reduced pressure. Recrystallization from MeOH gave the title compound (7.1g, 13.3mmol, 89%) as a yellow solid. 1H‐NMR (400MHz, CDCl3) δ[ppm]: 8.03 (d, J =1.9 Hz, 2H), 7.86 (d, J =9.1 Hz, 2H), 7.59 (d, J =9.1 Hz, 2H), 7.29 (dd, J =9.0, 2.0 Hz, 2H), 6.98 (d, J =9.0 Hz, 2H), 5.09 (d, J =6.9 Hz, 2H), 4.98 (d, J =6.9 Hz, 2H), 3.16 (bs, 6H). The analytical data are in accordance with the literature. 2.4 General procedure A: Grignard reaction A stirring solution of dibromo‐MOM‐BINOL (1.0 eq.) and PdCl2(dppf) (5mol%) in THF (200ml) was cooled to 0°C. n-Alkyl-MgX (5 eq.) was added dropwise and the reaction mixture was refluxed for 3h. The solution was allowed to cool to room temperature, was quenched with sat. aq. NH4Cl (150ml) and was extracted with EtOAc (3×100ml). The combined organic layers were washed with brine (100ml), dried over Na2SO4 and the solvent was removed under reduced pressure. Purification by column chromatography using PE/EtOAc as eluent gave desired products. 2.4.1 (S)‐2,2′‐Bis(methoxymethoxy)‐6,6′‐dioctyl‐1,1′‐binaphthalene (8) [13] Following the General Procedure A, subjection of dibromo‐MOM‐BINOL 7 (6.9g, 13.0mmol, 1.0 eq.) and n-Oct-MgBr (2.0M in Et2O, 32.5ml, 65.0mmol, 5 eq.), provided after purification by column chromatography [PE/EtOAc (5:1)] the title compound (7.6g, 12.7mmol, 98%) as a yellow oil. R f =0.52 (5:1) (SiO2, PE/EtOAc). 1H‐NMR (400 MHz, CDCl3) δ[ppm]: 7.86 (d, J =9.0 Hz, 2H), 7.62 (s, 2H), 7.52 (d, J =9.0 Hz, 2H), 7.07 (s, 4H), 5.04 (d, J =6.7 Hz, 2H), 4.94 (d, J =6.7 Hz, 2H), 3.13 (s, 6H), 2.72–2.68 (m, 4H), 1.70–1.60 (m, 4H), 1.36–1.20 (m, 20H), 0.89–0.85 (m, 6H). The analytical data are in accordance with the literature. 2.4.2 (S)‐2,2′‐Bis(methoxymethoxy)‐6,6′‐didodecyl‐1,1′‐binaphthalene (9) [26] Following the General Procedure A, subjection of dibromo‐MOM‐BINOL 7 (1.8g, 3.3mmol, 1.0 eq.) and n-dodecyl-MgBr (1.5M in Et2O, 11ml, 16.5mmol, 5 eq.), provided after purification by column chromatography [PE/EtOAc (10:1)] the title compound (2.0g, 2.8mmol, 85%) as a yellow oil. R f =0.53 (10:1) (SiO2, PE/EtOAc). 1H‐NMR (300 MHz, CDCl3) δ[ppm]: 7.99 (d, J =9.0 Hz, 2H), 7.79 (s, 2H), 7.76–7.64 (m, 2H), 7.42–7.18 (m, 4H), 5.17 (d, J =6.6 Hz, 2H), 5.08 (d, J =6.5 Hz, 2H), 3.27 (s, 6H), 2.88 (s, 4H), 1.86 (s, 4H), 1.64–1.43 (m, 36H), 1.10 (d, J =5.1 Hz, 6H). The analytical data are in accordance with the literature. 2.4.3 (S)‐2,2′‐Bis(methoxymethoxy)‐6,6′‐dioctadecyl‐1,1′‐binaphthalene (10) Following the General Procedure A, subjection of dibromo‐MOM‐BINOL 7 (1.8g, 3.3mmol, 1.0 eq.) and n-octadecyl-MgCl (0.5M in Et2O, 33ml, 16.5mmol, 5 eq.), provided after purification by column chromatography [PE/EtOAc (10:1)] the title compound (2.9g, 3.2mmol, 99%) as a yellow oil. R f =0.44 (10:1) (SiO2, PE/EtOAc). 1H‐NMR (300 MHz, CDCl3) δ[ppm]: 7.88 (d, J =9.0 Hz, 2H), 7.64 (s, 2H), 7.54 (d, J =9.0 Hz, 2H), 7.09 (s, 4H), 5.07 (d, J =6.4 Hz, 2H), 4.98 (d, J =6.4 Hz, 2H), 3.15 (s, 6H), 2.78–2.66 (m, 4H), 1.80–1.61 (m, 4H), 1.27 (bs, 60H), 0.89 (t, J =6.7 Hz, 6H). 13C‐NMR (100 MHz, CDCl3) δ[ppm]: 152.1, 138.6, 132.5, 130.1, 128.9, 128.8, 128.0, 126.2, 125.6, 121.6, 117.5, 117.4, 95.5, 55.9, 55.8, 35.9, 32.0, 31.4, 29.8, 29.7, 29.6, 29.5, 29.4, 22.7, 14.2. HRMS (ESI): m/z [M+Na]+ calcd for C60H94O4 +Na: 901.7044; found: 901.7035. 2.5 General procedure B: synthesis of diazido‐MOM‐BINOLs [15a] To a magnetically stirred solution of the corresponding MOM‐BINOL (4.50mmol, 1.00 eq.) and TMEDA (2.09g, 18.00mmol, 4.00 eq.) in Et2O (100ml), n-BuLi (1.6M in pentane, 7.7ml, 12.38mmol, 2.75 eq.) was added dropwise at 0°C. The reaction mixture was allowed to stir at room temperature for 1h and was cooled to 0°C again. Then, TsN3 (2.66g, 13.50mmol, 3.00 eq.) was added dropwise and the reaction mixture was kept at 0°C. After 1h, the cooling bath was removed and the solution was stirred at room temperature for 18h. The reaction mixture was diluted with water (20ml) and aqueous layer was extracted with CH2Cl2 (3×40ml). The combined organic layers were dried over Na2SO4, filtered and the solvent was removed under reduced pressure. The products were obtained by column chromatography on silica gel using petroleum ether (PE)/EtOAc/CH2Cl2 (30:2:1→20:2:1) as eluent. 2.5.1 (S)‐3,3′‐Diazido‐2,2′‐bis(methoxymethoxy)‐1,1′‐binaphthalene (4) [15a] Following the General Procedure B, subjection of (S)-MOM‐BINOL (1.66g, 4.5mmol, 1.0 eq.) with subsequent purification by column chromatography using PE/EtOAc/CH2Cl2 (30:2:1→20:2:1) as eluent gave the title compound (1.60g, 3.5mmol, 78%) as a brown solid. R f =0.42 (30:2:1) (SiO2, PE/EtOAc/CH2Cl2). 1H‐NMR (400 MHz, CDCl3) δ[ppm]: 7.82 (d, J =8.2 Hz, 2H), 7.68 (s, 2H), 7.43 (ddd, J =11.7, 5.8, 2.4 Hz, 2H), 7.25–7.21 (m, 2H), 7.15 (d, J =8.5 Hz, 2H), 4.87 (d, J =5.8 Hz, 2H), 4.76 (d, J =5.8 Hz, 2H), 2.65 (bs, 6H). 13C‐NMR (100MHz, CDCl3) δ[ppm]: 145.7, 133.1, 131.3, 130.8, 127.2, 126.7, 126.4, 126.0, 126.0, 117.7, 98.9, 56.4. The analytical data are in accordance with the literature. 2.5.2 (S)‐3,3′‐Diazido‐2,2′‐bis(methoxymethoxy)‐6,6′‐dioctyl‐1,1′‐binaphthalene (11) Following the General Procedure B, subjection of dioctyl‐MOM‐BINOL 8 (7.6g, 12.7mmol, 1.0 eq.) with subsequent purification by column chromatography using PE/EtOAc/CH2Cl2 (30:2:1) as eluent gave the title compound (8.1g, 11.9mmol, 94%) as a brown oil. R f =0.63 (20:2:1) (SiO2, PE/EtOAc/CH2Cl2). 1H‐NMR (300MHz, CDCl3) δ[ppm]: 7.65 (s, 2H), 7.60 (s,2H), 7.12 (s, 4H), 4.89 (dd, J =5.8, 1.0 Hz, 2H), 4.78 (dd, J =5.8, 1.0 Hz, 2H), 2.74 (t, J =7.6 Hz, 4H), 2.69 (s, 6H), 1.77 ‐ 1.64 (m, 4H), 1.30 (bs, 20H), 0.95–0.85 (m, 6H). 13C‐NMR (100 MHz, CDCl3) δ[ppm]: 145.1, 145.1, 140.7, 133.0, 131.1, 129.8, 127.6, 127.2, 126.3, 125.1, 117.2, 98.9, 56.4, 35.9, 32.0, 31.9, 31.2, 29.8, 29.7, 29.5, 29.4, 29.3, 22.8, 22.7, 22.7, 14.1, 11.5. HRMS (ESI): m/z [M+Na]+ calcd for C40H52N6O4 +Na: 703.3942; found: 703.3940. 2.5.3 ,3′‐Diazido‐2,2′‐bis(methoxymethoxy)‐6,6′‐didodecyl‐1,1′‐binaphthalene (12) Following the General Procedure B, subjection of dodecyl‐MOM‐BINOL 9 (2.0g, 2.8mmol, 1.0 eq.) with subsequent purification by column chromatography using PE/EtOAc/CH2Cl2 (30:2:1) as eluent gave the title compound (2.1g, 2.7mmol, 99%) as a brown oil. R f =0.50 (30:2:1) (SiO2, PE/EtOAc/CH2Cl2). 1H‐NMR (300MHz, CDCl3) δ[ppm]: 7.88–7.82 (m, 2H), 7.60 (d, J =3.2 Hz, 2H), 7.41 (d, J =8.1 Hz, 2H), 7.09–7.04 (m, 2H), 5.24–4.63 (m, 4H), 2.79–2.60 (m, 4H), 2.47 (s, 6H), 1.67–1.60 (m, 4H), 1.32–1.23 (m, 36H), 0.91–0.78 (m, 6H). 13C‐NMR (75 MHz, CDCl3) δ[ppm]: 152.2, 152.1, 146.2, 144.6, 140.5, 138.7, 138.6, 135.6, 133.3, 133.0, 132.9, 132.4, 131.2, 130.3, 130.1, 129.8, 129.3, 128.7, 128.3, 127.9, 127.6, 127.3, 126.2, 126.0, 125.5, 125.4, 125.1, 121.6, 120.0, 117.5, 117.1, 116.8, 116.5, 98.9, 95.5, 95.1, 70.4, 56.5, 56.4, 55.9, 55.8, 35.8, 31.9, 31.3, 31.2, 31.2, 30.8, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 22.7, 21.7, 21.6, 18.6, 14.1, 13.4. HRMS (ESI): m/z [M+Na]+ calcd for C48H68N6O4 +Na: 815.5194; found: 815.5187. 2.5.4 3,3′‐Diazido‐2,2′‐bis(methoxymethoxy)‐6,6′‐dioctadecyl‐1,1′‐binaphthalene (13) Following the General Procedure B, subjection of octadecyl‐MOM‐BINOL 10 (2.9g, 3.2mmol, 1.0 eq.) with subsequent purification by column chromatography using PE/EtOAc/CH2Cl2 (30:2:1) as eluent gave the title compound (2.2g, 2.3mmol, 70%) as a brown oil. R f =0.38 (30:2:1) (SiO2, PE/EtOAc/CH2Cl2). 1H‐NMR (300MHz, CDCl3) δ[ppm]: 7.89–7.83 (m, 2H), 7.62–7.55 (m, 2H), 7.41 (d, J =8.0 Hz, 2H), 7.07 (s, 2H), 4.84 (d, J =5.8 Hz, 2H), 4.73 (d, J =5.9 Hz, 2H), 2.77–2.67 (m, 4H), 2.65 (s, 6H), 1.66 (s, 4H), 1.25 (bs, 60H), 0.88 (t, J =6.7 Hz, 6H). 13C‐NMR (75MHz, CDCl3) δ[ppm]: 145.0, 140.8, 132.9, 131.0, 130.3, 129.7, 127.6, 127.1, 126.3, 125.0, 117.1, 98.9, 56.4, 35.9, 32.0, 31.1, 29.7, 29.6, 29.5, 29.4, 22.7, 21.8, 14.2. HRMS (ESI): m/z [M+Na]+ calcd for C60H92N6O4 +Na: 983.7072; found: 983.7064. 2.6 General procedure C: copper‐catalyzed cycloaddition of azides with alkynes (CuAAC) A stirring solution of azide (1.0 eq.), the corresponding alkyne (3 eq.), 0.04M aq. CuSO4 (8 mol%) and 0.12M aq. sodium ascorbate (24mol%) in a mixture of CH2Cl2/t-BuOH/H2O (1:1:1; 15–30ml; H2O from the CuSO4 and sodium ascorbate stock solution) was heated to 50°C. After complete consumption of the starting material as judged by TLC, the reaction mixture was allowed to cool to room temperature, was diluted with water (8ml) and the aqueous layer was extracted with CH2Cl2 (3×8ml). The combined organic layers were washed with 25% aq. ammonia (3×8ml) and brine (8ml). The organic layer was dried over Na2SO4, filtered and the solvent was removed under reduced pressure. Purification by column chromatography gave the desired products. 2.6.1 (S)‐1,1′‐(2,2′‐Bis(methoxymethoxy)‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4‐phenyl‐1H‐1,2,3-triazole) (5a) [15a] Following the General Procedure C, subjection of 3,3′‐diazido‐MOM‐BINOL 4 (0.90g, 2.0mmol, 1.0 eq.) and phenylacetylene (0.62g, 6.0mmol, 3.0 eq.) with subsequent purification by column chromatography using PE/EtOAc (20:1) as eluent gave the title compound (0.97g, 1.5mmol, 75%) as a grey solid. R f =0.29 (20:1) (SiO2, PE/EtOAc). 1H‐NMR (400 MHz, CDCl3) δ[ppm]: 8.52 (s, 2H), 8.45 (s, 2H), 8.03 (d, J =8.1 Hz, 2H), 7.96 (t, J =11.1, 4.0 Hz, 4H), 7.60–7.54 (m, 2H), 7.52–7.42 (m, 6H), 7.41–7.30 (m, 4H), 4.51 (d, J =5.8 Hz, 2H), 4.40 (d, J =5.8Hz, 2H), 2.57 (s, 6H). 13C‐NMR (100 MHz, CDCl3) δ[ppm]: 148.1, 146.4, 133.7, 130.4, 130.3, 129.0, 128.7, 128.5, 128.3, 126.8, 126.3, 126.2, 125.9, 122.2, 99.6, 60.4, 56.7, 21.1, 14.2. The analytical data are in accordance with the literature. 2.6.2 (S)‐1,1′‐(2,2′‐Bis(methoxymethoxy)‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4‐mesityl‐1H‐1,2,3-triazole) (5b) [15a] Following the General Procedure C, subjection of 3,3′‐diazido‐MOM‐BINOL 4 (0.46g, 1.0mmol, 1.0 eq.) and mesitylacetylene (0.44g, 3.0mmol, 3.0 eq.) with subsequent purification by column chromatography using PE/EtOAc (20:1) as eluent gave the title compound (0.26g, 0.35mmol, 35%) as a grey solid. R f =0.38 (20:1) (SiO2, PE/EtOAc). 1H‐NMR (400 MHz, CDCl3) δ[ppm]: 8.50 (d, J =6.5 Hz, 2H), 8.25–8.17 (m, 2H), 7.73 (s, 1H), 7.50–7.31 (m, 4H), 7.30–7.19 (m, 3H), 6.97 (s, 4H), 4.43 (m, 4H), 2.54 (s, 3H), 2.49 (s, 3H), 2.33 (s, 6H), 2.20 (bs, 12H). The analytical data are in accordance with the literature. 2.6.3 (S)‐1,1′‐(2,2′‐Bis(methoxymethoxy)‐6,6′‐dioctyl‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4-mesityl-1H- 1,2,3‐triazole) (5c) Following the General Procedure C, subjection of 3,3′‐diazido‐MOM‐BINOL 11 (1.44g, 2.11mmol, 1.0 eq.) and mesitylacetylene (0.91g, 6.32mmol, 3.0 eq.) with subsequent purification by column chromatography using PE/EtOAc (4:1) as eluent gave the title compound (0.97g, 1.01mmol, 48%) as a brown solid. R f =0.55 (4:1) (SiO2, PE/EtOAc). 1H‐NMR (400 MHz, CDCl3) δ[ppm]: 8.36 (s, 1H), 8.07 (s, 1H), 7.99 (s, 1H), 7.75 (s, 1H), 7.71 (s, 1H), 7.64 (s, 1H), 7.24–7.21 (m, 2H), 7.15 (dd, J =8.7, 1.5 Hz, 1H), 6.99 (s, 2H), 6.95 (d, J =8.7 Hz, 1H), 6.79 (d, J =19.1 Hz, 2H), 4.52 (d, J =5.3 Hz, 1H), 4.41 (d, J =5.3 Hz, 1H), 4.04 (d, J =5.9 Hz, 1H), 3.99 (d, J =5.9 Hz, 1H), 2.79 ‐ 2.68 (m, 4H), 2.48 (s, 3H), 2.35 (s, 3H), 2.22 (bs, 7H), 2.19 (s, 3H), 2.16 (s, 3H), 2.03 (s, 3H), 1.75–1.64 (m, 6H), 1.41 ‐ 1.18 (m, 20H), 0.88 (t, J =6.8 Hz, 6H). 13C‐NMR (100 MHz, CDCl3) δ[ppm]: 147.7, 145.7, 145.6, 141.3, 141.2, 139.2, 138.8, 138.7, 138.3, 138.1, 137.8, 133.8, 132.5, 131.8, 130.5, 130.1, 130.1, 130.0, 129.9, 129.6, 128.5, 128.4, 128.3, 128.3, 126.9, 126.8, 126.6, 126.4, 126.2, 126.1, 126.0, 125.4, 125.1, 122.8, 99.7, 98.9, 56.3, 56.2, 35.8, 31.9, 31.1, 29.5, 29.4, 29.4, 29.3, 29.3, 29.3, 22.7, 21.7, 21.0, 20.9, 20.5, 20.4, 14.1. HRMS (ESI): m/z [M+H]+ calcd for C62H76N6O4P+H: 969.6001; found: 969.6003. 2.6.4 (S)‐1,1′‐(2,2′‐Bis(methoxymethoxy)‐6,6′‐dioctyl‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4-(2,4,6‐triiso-propylphenyl)‐1H‐1,2,3‐triazole) (5d) Following the General Procedure C, subjection of 3,3′‐diazido‐MOM‐BINOL 11 (1.36g, 2.0mmol, 1.0 eq.) and 2,4,6-triisopropylbenzene acetylene (1.37g, 6.0mmol, 3.0 eq.) with subsequent purification by column chromatography using PE/EtOAc (10:1) as eluent gave the title compound (1.33g, 1.16mmol, 58%) as a brown solid. R f =0.22 (10:1) (SiO2, PE/EtOAc). 1H‐NMR (300 MHz, CDCl3) δ[ppm]: 8.44 (d, J =5.9 Hz, 2H), 8.19 (d, J =1.5 Hz, 2H), 7.78 (s, 2H), 7.27 (d, J =0.7 Hz, 2H), 7.17 (dd, J =10.0, 0.8 Hz, 2H), 7.10 (s, 4H), 4.50 (d, J =5.4 Hz, 2H), 4.38 (d, J =5.2 Hz, 2H), 3.23 (s, 2H), 2.97–2.90 (m, 4H), 2.85–2.67 (m, 12H), 2.54 (s, 6H), 1.73–1.65 (m, 6H), 1.43–1.22 (m, 20H), 1.18–1.11 (m, 12H), 1.00–0.73 (m, 6H). 13C‐NMR (100 MHz, CDCl3) δ[ppm]: 149.8, 148.7, 148.6, 145.5, 145.3, 141.5, 130.7, 130.6, 130.4, 129.7, 129.5, 128.6, 126.8, 126.7, 125.1, 125.0, 122.1, 120.7, 99.0, 60.4, 56.4, 56.0, 41.4, 36.1, 35.9, 34.5, 34.3, 34.1, 31.9, 31.6, 31.1, 30.6, 29.5, 29.3, 29.1, 27.7, 24.3, 24.2, 24.1, 24.0, 23.9, 23.8, 22.7, 22.6, 20.5, 19.5, 18.8, 14.3, 14.2, 14.1, 11.5. HRMS (ESI): m/z [M+H]+ calcd for C74H100N6O4 +H: 1137.7879; found: 1137.7878. 2.6.5 (S)‐1,1′‐(2,2′‐Bis(methoxymethoxy)‐6,6′‐dioctyl‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4-(adaman-tyl)‐1H‐1,2,3‐triazole) (5e) Following the General Procedure C, subjection of 3,3′‐diazido‐MOM‐BINOL 11 (0.64g, 0.93mmol, 1.0 eq.) and adamantyl acetylene (0.44g, 2.79mmol, 3.0 eq.) with subsequent purification by column chromatography using PE/EtOAc (5:1) as eluent gave the title compound (0.43g, 0.43mmol, 46%) as a brown solid. R f =0.45 (5:1) (SiO2, PE/EtOAc). 1H‐NMR (300MHz, CDCl3) δ[ppm]: 7.82 (d, J =9.0 Hz, 2H), 7.58 (s, 2H), 7.48 (d, J =9.0 Hz, 2H), 7.24 (d, J =8.1 Hz, 2H), 7.03 (s, 4H), 5.00 (d, J =6.7 Hz, 2H), 4.90 (d, J =6.7 Hz, 2H), 3.09 (s, 6H), 2.72–2.61 (m, 4H), 2.09–2.02 (m, 4H), 1.79–1.74 (m, 10H), 1.65–1.61 (m, 20H), 1.21 (bs, 20H), 0.80 (s, 6H). HRMS (ESI): m/z [M+H]+ calcd for C64H84N6O4 +H: 1001.6627; found: 1001.6637. 2.6.6 (S)‐1,1′‐2,2′‐Bis((methoxymethoxy)‐6,6′‐dioctyl‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4‐(4‐bromo-2,6‐diisopropylphenyl)‐1H‐1,2,3‐triazole) (5f) Following the General Procedure C, subjection of 3,3′‐diazido‐MOM‐BINOL 11 (1.01g, 1.5mmol, 1.0 eq.) and 1-ethynyl-2-bromo-2,6-diisopropylbenzene (0.98g, 3.7mmol, 2.5 eq.) with subsequent purification by column chromatography using PE/EtOAc (10:1) as eluent gave the title compound (1.27g, 1.05mmol, 71%) as a brown solid. R f =0.51 (10:1) (SiO2, PE/EtOAc). 1H‐NMR (300 MHz, CDCl3) δ[ppm]: 8.53 (s, 2H), 8.32 (s, 2H), 7.70 (s, 4H), 7.37–7.12 (m, 6H), 4.52 (d, J =5.8 Hz, 2H), 4.41 (d, J =5.8 Hz, 2H), 3.61–3.51 (m, 4H), 2.76 (dd, J =15.2, 7.6 Hz, 4H), 2.58 (s, 6H), 1.75–1.62 (m, 4H), 1.35–1.31 (m, 24H), 1.29–1.18 (m, 20H), 0.87 (t, J =6.5 Hz, 6H). 13C‐NMR (75MHz, CDCl3) δ[ppm]: 148.6, 147.7, 145.7, 141.7, 132.2, 130.6, 130.3, 130.0, 129.5, 126.9, 126.8, 126.6, 126.1, 126.0, 122.1, 121.7, 99.7, 56.7, 35.9, 33.8, 31.9, 31.1, 29.5, 29.4, 29.3, 23.1, 22.7, 14.1. HRMS (ESI): m/z [M+H]+ calcd for C68H86Br2N6O4 +H: 1209.5150; found: 1209.5138. 2.6.7 (S)‐1,1′‐2,2′‐Bis(methoxymethoxy)‐(6,6′‐didodecyl‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4-mesityl‐1H‐1,2,3‐triazole) (5g) Following the General Procedure C, subjection of 3,3′‐diazido‐MOM‐BINOL 12 (1.72g, 2.2mmol, 1.0 eq.) and mesityl acetylene (0.95g, 6.6mmol, 3.0 eq.) with subsequent purification by column chromatography using PE/EtOAc (20:1) as eluent gave the title compound (1.76g, 1.8mmol, 80%) as a brown solid. R f =0.38 (20:1) (SiO2, PE/EtOAc). 1H‐NMR (300 MHz, CDCl3) δ[ppm]: 7.82 (d, J =9.1 Hz, 2H), 7.58 (s, 2H), 7.48 (d, J =9.0 Hz, 2H), 7.22 (s, 2H), 7.03 (s, 4H), 6.82 (s, 2H), 5.01 (d, J =6.7 Hz, 2H), 4.90 (d, J =6.7 Hz, 2H), 3.09 (s, 6H), 2.74–2.61 (m, 4H), 2.37 (s, 9H), 2.24 (s, 9H), 1.66–1.57 (m, 4H), 1.20 (bs, 36H), 0.89–0.77 (m, 6H). 13C‐NMR (75 MHz, CDCl3) δ[ppm]: 152.3, 145.9, 145.6, 144.7, 141.0, 138.9, 138.2, 137.9, 137.8, 132.1, 130.7, 130.6, 130.4, 130.3, 129.8, 129.2, 128.8, 128.4, 127.9, 126.8, 126.2, 125.5, 119.4, 117.5, 99.0, 95.5, 56.6, 56.0, 55.8, 35.9, 31.9, 31.3, 31.2, 29.7, 29.7, 29.6, 29.6, 29.4, 22.7, 21.2, 20.8, 14.2. HRMS (ESI): m/z [M+H]+ calcd for C70H92N6O4 +H: 1081.7253; found: 1081.7245. 2.6.8 (S)‐1,1′‐(2,2′‐Bis(methoxymethoxy)‐6,6′‐dioctadecyl‐[1,1′‐binaphthalene]‐3,3′‐diyl)bis(4‐mesityl‐1H‐1,2,3‐triazole) (5h) Following the General Procedure C, subjection of 3,3′‐diazido‐MOM‐BINOL 13 (2.24g, 2.3mmol, 1.0 eq.) and mesityl acetylene (1.00g, 6.9mmol, 3.0 eq.) with subsequent purification by column chromatography using PE/EtOAc (10:1) as eluent gave the title compound (1.89g, 1.5mmol, 66%) as a brown solid. R f =0.42 (10:1) (SiO2, PE/EtOAc). 1H‐NMR (300MHz, CDCl3) δ[ppm]: 8.41 (s, 2H), 8.19 (s, 2H), 7.78 (s, 2H), 7.27 (s, 4H), 6.97 (s, 4H), 4.49 (d, J =5.5 Hz, 2H), 4.38 (d, J =5.5 Hz, 2H), 2.83–2.70 (m, 4H), 2.54 (s, 6H), 2.33 (s, 6H), 2.20 (bs, 12H), 1.76–1.65 (m, 4H), 1.26 (bs, 60H), 0.88 (t, J =6.9 Hz, 6H). 13C‐NMR (75MHz, CDCl3) δ[ppm]: 145.9, 145.4, 141.5, 138.3, 137.8, 132.0, 130.6, 130.3, 129.8, 128.5, 126.9, 126.8, 126.7, 126.2, 125.6, 125.0, 99.1, 56.5, 35.9, 32.0, 31.1, 29.8, 29.7, 29.6, 29.5, 29.4, 22.7, 21.2, 20.9, 14.2. HRMS (ESI): m/z [M+H]+ calcd for C82H116N6O4 +H: 1249.9131; found: 1249.9156. 2.7 General procedure D: MOM‐deprotection of BINOL derivatives A stirring solution of MOM‐protected BINOL derivative (1 eq.) in a 1:2 mixture of CH2Cl2/MeOH (33 ml) was treated with 12M aq. HCl (38 eq.). The reaction mixture was stirred for 12h at 50°C. The solution was allowed to cool to room temperature, was neutralized with sat. aq. NaHCO3 and extracted with CH2Cl2 (3×30ml). The combined organic layers were dried over Na2SO4, filtered and the solvent was removed under reduced pressure. The desired products were obtained by precipitation (CH2Cl2‐cyclohexane) and filtration. 2.7.1 (S)‐3,3′‐Bis(4‐phenyl‐1H‐1,2,3‐triazol‐1‐yl)‐[1,1′‐binaphthalene]‐2,2′‐diol (6a) [15a] Following the General procedure D, the deprotection of triazolyl‐MOM‐BINOL 5a (0.97g, 1.5mmol, 1.0 eq.) gave the title compound (0.69g, 1.2mmol, 80%) as a brown solid. 1H‐NMR (300 MHz, DMSO-d6) δ[ppm]: 9.58 (s, 2H), 9.05 (s, 2H), 8.46 (s, 2H), 8.11 (d, J =7.4 Hz, 2H), 8.02–7.97 (m, 4H), 7.55–7.34 (m, 10H), 7.06 (d, J =8.2 Hz, 2H). The analytical data are in accordance with the literature. 2.7.2 (S)‐3,3′‐Bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐[1,1′‐binaphthalene]‐2,2′‐diol (6b) [15a] Following the General procedure D, the deprotection of triazolyl‐MOM‐BINOL 5b (257.3mg, 0.35mmol, 1.0 eq.) gave the title compound (211.5mg, 0.32mmol, 91%) as a brown solid. 1H‐NMR (300 MHz, DMSO-d6) δ[ppm]: 9.31 (s, 2H), 8.53–8.50 (m, 2H), 8.12–7.99 (m, 2H), 7.79–7.73 (m, 2H), 7.34–7.25 (m, 4H), 6.97 (s, 4H), 6.85 (s, 2H), 2.21 (s, 6H), 2.14 (bs, 12H). The analytical data are in accordance with the literature. 2.7.3 (S)‐3,3′‐Bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐6,6′‐dioctyl‐[1,1′‐binaphthalene]‐2,2′‐diol (6c) Following the General procedure D, the deprotection of triazolyl‐MOM‐BINOL 5c (0.97g, 1.0mmol, 1.0 eq.) gave the title compound (0.88g, 0.99mmol, 99%) as a brown solid. 1H‐NMR (400 MHz, CDCl3) δ[ppm]: 8.38–7.95 (m, 4H), 7.74–7.56 (m, 2H), 7.29–7.08 (m, 4H), 7.01–6.79 (m, 4H), 2.88–2.51 (m, 4H), 2.37–2.24 (m, 6H), 2.22–1.88 (m, 12H), 1.78–1.52 (m, 4H), 1.45–1.18 (m, 20H), 0.95–0.81 (m, 6H). 13C‐NMR (100 MHz, CDCl3) δ[ppm]: 145.6, 144.7, 139.6, 138.5, 137.9, 131.9, 129.7, 128.6, 128.4, 128.3, 126.9, 126.3, 125.1, 124.8, 122.6, 120.4, 118.2, 35.9, 32.0, 31.5, 31.3, 29.6, 29.5, 29.4, 22.8, 21.2, 20.8, 20.3, 19.7, 14.2. HRMS (ESI): m/z [M−H]− calcd for C58H67N6O2 ‐ H: 879.5331; found: 879.5333. 2.7.4 (S)‐6,6′‐Dioctyl‐3,3′‐bis(4‐(2,4,6‐triisopropylphenyl)‐1H‐1,2,3‐triazol‐1‐yl)‐[1,1′-binaphthalene]- 2,2′‐diol (6d) Following the General procedure D, the deprotection of triazolyl‐MOM‐BINOL 5d (1.68g, 1.5mmol, 1.0 eq.) gave the title compound (1.43g, 1.36mmol, 91%) as a brown solid. 1H‐NMR (300 MHz, CDCl3) δ[ppm]: 9.50 (s, 2H), 8.26 (s, 2H), 8.17 (s, 2H), 7.74 (s, 2H), 7.23 (s, 4H), 7.14 (s, 4H), 2.97 (dd, J =13.7, 6.9 Hz, 3H), 2.83–2.60 (m, 14H), 1.73–1.64 (m, 8H), 1.27 (bs, 20H), 1.21–1.15 (m, 34H), 0.88 (t, J =6.4Hz, 6H). 13C‐NMR (100MHz, CDCl3) δ[ppm]: 152.2, 150.3, 150.0, 148.8, 147.6, 145.7, 145.4, 144.6, 144.4, 139.8, 138.3, 132.1, 131.8, 130.5, 129.9, 129.5, 129.4, 128.8, 128.7, 128.6, 128.5, 128.3, 128.1, 127.0, 126.9, 126.6, 125.4, 125.0, 124.9, 124.8, 124.5, 124.4, 123.6, 122.3, 121.7, 121.6, 120.9, 120.8, 119.7, 118.5, 118.1, 117.1, 112.2, 53.5, 35.9, 34.6, 34.4, 32.0, 31.5, 31.3, 30.8, 30.7, 30.0, 29.6, 29.5, 29.4, 29.3, 24.3, 24.2, 24.1, 23.9, 22.8, 21.7, 14.2. HRMS (ESI): m/z [M−H]+ calcd for C70H92N6O2 +H: 1049.7355; found: 1049.7351. 2.7.5 (S)‐6,6′‐dioctyl‐3,3′‐bis(4‐(adamantyl)‐1H‐1,2,3‐triazol‐1‐yl)‐[1,1′-binaphthalene]‐2,2′‐diol (6e) Following the General procedure D, the deprotection of triazolyl‐MOM‐BINOL 5e (0.43g, 0.43mmol, 1.0 eq.) gave the title compound (0.37g, 0.40mmol, 93%) as a brown solid. 1H‐NMR (300MHz, CDCl3) δ[ppm]: 9.57 (s, 2H), 8.05 (s, 2H), 8.02 (s, 2H), 7.67 (s, 2H), 7.18–7.13 (m, 4H), 2.71 (dd, J =14.6, 6.5 Hz, 6H), 2.07 (s, 15H), 1.89 (d, J =2.9 Hz, 2H), 1.82 (bs, 15H), 1.25 (bs, 20H), 0.92–0.84 (m, 6H). HRMS (ESI): m/z [M−H]+ calcd for C60H76N6O2 +H: 913.6103; found: 913.6105. 2.7.6 (S)‐3,3′‐Bis(4‐(4‐bromo‐2,6‐diisopropylphenyl)‐1H‐1,2,3‐triazol‐1‐yl)‐6,6′‐dioctyl‐[1,1′-binaphthalene]‐2,2′‐diol (6f) Following the General procedure D, the deprotection of triazolyl‐MOM‐BINOL 5f (1.27g, 1.05mmol, 1.0 eq.) gave the title compound (0.82g, 0.73mmol, 70%) as a brown solid. 1H‐NMR (300MHz, CDCl3) δ[ppm]: 8.94 (s, 2H), 8.58 (s, 2H), 8.24 (s, 2H), 7.75–7.60 (m, 4H), 7.25–7.08 (m, 4H), 3.63–3.53 (m, 4H), 2.76–2.70 (m, 4H), 1.77–1.62 (m, 4H), 1.36–1.32 (m, 24H), 1.31–1.22 (m, 20H), 0.87 (t, J =5.8 Hz, 6H). 13C‐NMR (100 MHz, CDCl3) δ[ppm]: 148.7, 147.7, 144.4, 139.9, 131.6, 129.9, 128.9, 128.2, 127.1, 126.8, 124.7, 121.9, 121.8, 120.0, 119.2, 118.0, 35.8, 33.7, 31.9, 31.1, 29.5, 29.3, 29.2, 23.0, 22.7, 14.1. HRMS (ESI): m/z [M−H]+ calcd for C64H78Br2N6O2 +H: 1121.4626; found: 1121.4615. 2.7.7 (S)‐3,3′‐Bis(4‐mesityl‐1H‐1,2,3-triazol‐1‐yl)‐6,6′‐didodecyl‐[1,1′‐binaphthalene]‐2,2′‐diol (6g) Following the General procedure D, the deprotection of triazolyl‐MOM‐BINOL 5 g (1.76g, 1.8mmol, 1.0 eq.) gave the title compound (1.26g, 1.26mmol, 70%) as a brown solid. 1H‐NMR (300MHz, CDCl3) δ[ppm]: 8.32–8.18 (m, 2H), 7.95–7.59 (m, 4H), 7.34 (dd, J =8.8, 2.0 Hz, 2H), 7.25–7.06 (m, 4H), 7.00 (d, J =2.1 Hz, 2H), 2.77–2.70 (m, 4H), 2.36 (s, 6H), 2.20 (s, 12H), 1.78 ‐ 1.58 (m, 4H), 1.42–1.19 (m, 36H), 0.91–0.81 (m, 6H). 13C‐NMR (100 MHz, CDCl3) δ[ppm]: 145.8, 144.7, 144.5, 140.1, 139.8, 138.7, 138.6, 138.5, 138.4, 137.9, 131.7, 131.6, 130.8, 130.6, 130.1, 129.8, 129.6, 129.5, 129.0, 128.8, 128.6, 128.5, 128.2, 127.9, 126.9, 126.3, 126.1, 125.0, 124.7, 124.2, 122.8, 121.3, 118.4, 117.8, 117.6, 116.1, 112.2, 110.9, 35.8, 32.0, 31.5, 31.3, 29.8, 29.7, 29.6, 29.5, 29.4, 22.7, 21.2, 20.8, 14.2. HRMS (ESI): m/z [M−H]+ calcd for C66H84N6O2 +H: 993.6729; found: 993.6719. 2.7.8 (S)‐3,3′‐Bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐6,6′‐dioctadecyl‐[1,1′‐binaphthalene]‐2,2′-diol (6h) Following the General procedure D, the deprotection of triazolyl‐MOM‐BINOL 5 h (1.89g, 1.5mmol, 1.0 eq.) gave the title compound (1.48g, 1.27mmol, 85%) as a brown solid. 1H‐NMR (300MHz, CDCl3) δ[ppm]: 8.24 (s, 2H), 8.16 (s, 2H), 7.72 (s, 2H), 7.21 (s, 4H), 7.00 (s, 4H), 2.87–2.63 (m, 4H), 2.35 (s, 6H), 2.20 (bs, 12H), 1.76–1.57 (m, 4H), 1.25 (bs, 60H), 0.88 (t, J =6.7 Hz, 6H). 13C‐NMR (100 MHz, CDCl3) δ[ppm]: 145.9, 144.5, 139.8, 138.7, 137.9, 131.6, 129.8, 128.6, 128.1, 126.7, 126.1, 124.7, 121.9, 119.5, 118.4, 35.9, 32.0, 31.2, 29.8, 29.7, 29.6, 29.4, 22.7, 21.2, 20.8, 14.2. HRMS (ESI): m/z [M−H]+ calcd for C78H108N6O2 +H: 1161.8607; found: 1161.8619. 2.8 General procedure E: Synthesis of phosphoric acids [13] To a stirring solution of triazolyl diol (1 eq.) in pyridine (0.1 M) was added phosphoryl chloride (4 eq.) dropwise under an atmosphere of N2. The reaction mixture was heated to 95°C. Upon complete consumption of the starting material, as judged by TLC, the reaction mixture was allowed to cool to room temperature. H2O (1.0 M) was added dropwise at 0°C and the mixture was again stirred at 95°C. Upon complete consumption of the starting material, as judged by TLC, the reaction mixture was allowed to cool to room temperature and the mixture was diluted with CH2Cl2 (10 ml) and 1.0M HCl (5ml). The aqueous layer was separated with a Whatman© phase separator. The organic layer was dried over Na2SO4, filtered and the solvent was removed under reduced pressure. The desired products were obtained by column chromatography. 2.8.1 (S)‐4‐Hydroxy‐2,6‐bis(4‐phenyl‐1H‐1,2,3‐triazol‐1‐yl)dinaphtho[2,1‐d:1′,2′‐f-1,3,2]dioxaphos-phepine 4‐oxide (1a) Following the General Procedure E, subjection of triazolyl diol 6a (0.57g, 1.0mmol, 1.0 eq.) and phosphorylchloride (0.61g, 4.0mmol, 4.0 eq.) with subsequent purification by column chromatography using CH2Cl2/MeOH (50:1) as eluent gave the title compound (0.49g, 0.77mmol, 77%) as a brown solid. R f =0.33 (50:1) (SiO2, CH2Cl2/MeOH). 1H‐NMR (400MHz, DMSO‐d6) δ[ppm]: 9.74 (s, 2H), 8.69 (s, 2H), 8.15–7.99 (m, 2H), 7.95 (d, J =7.3 Hz, 4H), 7.57–7.44 (m, 8H), 7.44–7.33 (m, 2H), 7.28 (d, J =5.2 Hz, 2H). 13C‐NMR (100MHz, DMSO-d6) δ[ppm]: 154.0, 147.2, 146.5, 146.4, 141.7, 141.6, 133.8, 131.6, 130.5, 130.5, 129.9, 129.2, 129.1, 129.0, 128.9, 128.9, 128.7, 128.2, 128.1, 127.7, 127.3, 127.2, 126.5, 126.1, 125.4, 125.3, 124.2, 124.2, 124.1, 123.5, 123.3, 123.2, 123.2, 116.6. 31P‐NMR (162 MHz, DMSO‐d6) δ[ppm]: 5.19. HRMS (ESI): m/z [M+H]+ calcd for C36H23N6O4P+H: 635.1591; found: 635.1593. 2.8.2 (S)‐4‐Hydroxy‐2,6‐bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)dinaphtho[2,1‐d:1′,2′‐f-1,3,2]dioxaphos-phepine 4‐oxide (1b) Following the General Procedure E, subjection of triazolyl diol 6b (206.8mg, 0.32mmol, 1.0 eq.) and phosphorylchloride (196.3mg, 1.30mmol, 4.0 eq.) with subsequent purification by column chromatography using CH2Cl2/MeOH (20:1) as eluent gave the title compound (63.1mg, 0.09mmol, 27%) as a brown solid. R f =0.29 (20:1) (SiO2, CH2Cl2/MeOH). 1H‐NMR (400 MHz, CDCl3) δ[ppm]: 8.92–6.54 (bm, 28H) (should be 17H), 1.38–1.11 (bm, 12H), 0.92–0.77 (bm, 6H). 13C‐NMR (100MHz, CDCl3) δ[ppm]: no signals could be recorded after 7000 scans. 31P‐NMR (162 MHz, CDCl3) δ[ppm]: 2.72. HRMS (ESI): m/z [M+H]+ calcd for C42H35N6O4P+H: 719.2530; found: 719.2536. 2.8.3 (4R,11bS)‐4‐Hydroxy‐2,6‐bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐9,14‐dioctyldinaphtho[2,1‐d:1′,2′‐f-1,3,2]dioxaphosphepine 4‐oxide (1c) Following the General Procedure E, subjection of triazolyl diol 6c (876.0mg, 0.99mmol, 1.0 eq.) and phosphorylchloride (607.0mg, 3.96mmol, 4.0 eq.) with subsequent purification by column chromatography using CH2Cl2/MeOH (20:1) as eluent gave the title compound (788.9mg, 0.83mmol, 84%) as a brown solid. R f =0.33 (20:1) (SiO2, CH2Cl2/MeOH). 1H‐NMR (400 MHz, CDCl3) δ[ppm]: 8.31–7.90 (m, 3H), 7.79–7.49 (m, 2H), 7.42–7.10 (m, 3H), 7.06–6.62 (m, 6H), 2.89–2.67 (m, 4H), 2.64 (s, 3H), 2.35 (s, 3H), 2.20 (s, 6H), 1.92 (s, 6H), 1.75–1.52 (m, 4H), 1.29 (bs, 20H), 0.89 (t, J =6.4 Hz, 6H). 13C‐NMR (100 MHz, CDCl3) δ[ppm]: 145.9, 144.5, 140.8, 139.7, 138.6, 137.8, 137.7, 131.6, 130.3, 129.7, 128.5, 128.4, 128.1, 126.7, 124.7, 123.4, 121.9, 119.5, 118.4, 35.8, 35.7, 31.9, 31.2, 30.9, 29.5, 29.4, 29.3, 29.3, 29.2, 22.7, 22.6, 21.1, 21.0, 20.8, 20.6, 14.1, 14.1. 31P‐NMR (162 MHz, CDCl3) δ[ppm]: 0.99. HRMS (ESI): m/z [M+H]+ calcd for C58H66N6O4P+H: 943.5034; found: 943.5029. 2.8.4 (4R,11bS)‐4‐hydroxy‐9,14‐dioctyl‐2,6‐bis(4‐(2,4,6‐triisopropylphenyl)‐1H‐1,2,3‐triazol‐1-yl) dinaphtho[2‐d:1′,2′‐f][2,1‐d:1′,2′‐f][1,3,2]dioxaphosphepine 4‐oxide (1d) Following the General Procedure E, subjection of triazolyl diol 6d (876.0mg, 0.99mmol, 1.0 eq.) and phosphorylchloride (607.0mg, 3.96mmol, 4.0 eq.) with subsequent purification by column chromatography using CH2Cl2/MeOH (20:1) as eluent gave the title compound (788.9mg, 0.83mmol, 84%) as a brown solid. R f =0.33 (20:1) (SiO2, CH2Cl2/MeOH). 1H‐NMR (300MHz, CDCl3) δ[ppm]: 8.59 (s, 2H), 8.27 (s, 2H), 7.69 (s, 2H), 7.20 (t, J =7.3 Hz, 4H), 7.03 (s, 4H), 2.92 (dt, J =13.7, 6.9 Hz, 2H), 2.79–2.68 (m, 8H), 1.67 (s, 4H), 1.41–1.27 (m, 32H), 1.08–1.03 (m, 22H), 0.91–0.86 (m, 8H). 13C‐NMR (75 MHz, CDCl3) δ[ppm]: 149.6, 148.8, 145.0, 141.2, 130.5, 129.3, 127.0, 126.7, 120.6, 35.7, 34.5, 31.9, 31.1, 30.5, 29.5, 29.4, 29.3, 24.2, 24.1, 22.7, 14.2. 31P‐NMR (121 MHz, CDCl3) δ[ppm]: 3.11. HRMS (ESI): m/z [M−H]+ calcd for C70H91N6O4P+H: 1111.6912; found: 1111.6916. 2.8.5 (4R,11bS)‐4‐hydroxy‐9,14‐dioctyl‐2,6‐bis(4‐(adamantyl)‐1H‐1,2,3‐triazol‐1-yl)dinaphtho [2‐d:1′,2′‐f][2,1‐d:1′,2′‐f][1,3,2]dioxaphosphepine 4‐oxide (1e) Following the General Procedure E, subjection of triazolyl diol 6e (366.7mg, 0.4mmol, 1.0 eq.) and phosphorylchloride (245.3mg, 1.6mmol, 4.0 eq.) with subsequent purification by column chromatography using CH2Cl2/MeOH (20:1) as eluent gave the title compound (320.3mg, 0.33mmol, 83%) as a brown solid. R f =0.5 (20:1) (SiO2, CH2Cl2/MeOH). 1H‐NMR (300 MHz, CDCl3) δ[ppm]: 8.39–7.82 (m, 4H), 7.61–7.55 (m, 2H), 7.16–6.81 (m, 4H), 2.67 (t, J =7.5 Hz, 4H), 2.20–1.96 (m, 6H), 1.91–1.52 (m, 22H), 1.40–1.07 (m, 26H), 0.82 (dd, J =7.7, 5.3 Hz, 6H). 13C‐NMR (100 MHz, CDCl3) δ[ppm]: 158.0, 144.6, 139.4, 131.5, 130.4, 129.5, 129.1, 128.0, 126.6, 124.7, 118.6, 42.7, 42.4, 42.1, 36.6, 36.5, 36.3, 35.8, 32.8, 31.9, 31.2, 29.7, 29.5, 29.4, 29.4, 29.3, 28.4, 28.3, 27.9, 22.7, 14.2. 31P‐NMR (162 MHz, CDCl3) δ[ppm]: 3.34. HRMS (ESI): m/z [M−H]+ calcd for C60H75N6O4P+H: 975.5660; found: 975.5663. 2.8.6 (4R,11bS)‐2,6‐Bis(4‐(4‐bromo‐2,6‐diisopropylphenyl)‐1H‐1,2,3‐triazol‐1‐yl)‐4‐hydroxy-9,14‐dioctyldinaphtho[2‐d:1′,2′‐f][2,1‐d:1′,2′‐f][1,3,2]dioxaphosphepine 4‐oxide (1f) Following the General Procedure E, subjection of triazolyl diol 6f (821.3mg, 0.73mmol, 1.0 eq.) and phosphorylchloride (447.7mg, 2.92mmol, 4.0 eq.) with subsequent purification by column chromatography using CH2Cl2/MeOH (20:1) as eluent gave the title compound (711.3mg, 0.6mmol, 82%) as a brown solid. R f =0.52 (20:1) (SiO2, CH2Cl2/MeOH). 1H‐NMR (300 MHz, CDCl3) δ[ppm]: 8.61 (s, 2H), 8.19 (s, 2H), 7.74–7.28 (m, 6H), 7.22–6.97 (m, 4H), 3.78–3.44 (m, 4H), 2.79–2.49 (m, 4H), 1.63 (s, 4H), 1.44–1.14 (m, 44H), 0.90 (t, J =6.5 Hz, 6H). 13C‐NMR (75MHz, CDCl3) δ[ppm]: 148.5, 148.4, 147.4, 144.6, 139.7, 131.7, 129.9, 128.8, 128.2, 126.9, 126.8, 124.9, 124.5, 121.8, 120.6, 119.7, 117.7, 35.8, 33.7, 32.0, 31.2, 29.5, 29.4, 29.3, 23.0, 22.7, 14.2. 31P‐NMR (121 MHz, CDCl3) δ[ppm]: 3.25. HRMS (ESI): m/z [M−H]+ calcd for C64H77Br2N6O4P+H: 1183.4183; found: 1183.4168. 2.8.7 (4R,11bS)‐2,6‐Bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐4‐hydroxy–9,14‐didodecyldinaphtho [2‐d:1′,2′‐f][2,1‐d:1′,2′‐f][1,3,2]dioxaphosphepine 4‐oxide (1g) Following the General Procedure E, subjection of triazolyl diol 6 g (1.26g, 1.26mmol, 1.0 eq.) and phosphorylchloride (0.77g, 5.04mmol, 4.0 eq.) with subsequent purification by column chromatography using CH2Cl2/MeOH (20:1) as eluent gave the title compound (185.9mg, 0.18mmol, 14%) as a brown solid. R f =0.14 (20:1) (SiO2, CH2Cl2/MeOH). 1H‐NMR (300MHz, CDCl3) δ[ppm]: 8.33–8.16 (m, 4H), 7.63 (s, 2H), 7.08 (s, 4H), 6.76 (s, 4H), 2.70 (s, 4H), 2.26 (s, 6H), 2.02 (s, 12H), 1.65 (s, 4H), 1.29 (bs, 36H), 0.90 (t, J =6.6 Hz, 6H). 13C‐NMR (75 MHz, CDCl3) δ[ppm]: 145.1, 141.1, 141.0, 140.8, 137.7, 137.6, 130.4, 130.2, 129.0, 128.8, 128.3, 126.9, 126.6, 126.5, 126.4, 125.8, 123.5, 35.6, 31.9, 30.9, 29.7, 29.6, 29.5, 29.4, 29.3, 22.6, 21.0, 20.7, 14.0. 31P‐NMR (121 MHz, CDCl3) δ[ppm]: 2.37. HRMS (ESI): m/z [M−H]+ calcd for C66H83N6O4P+H: 1055.6286; found: 1055.6273. 2.8.8 (4R,11bS)‐2,6‐Bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐4‐hydroxy‐9,14‐dioctadecyldinaphtho [2‐d:1′,2′‐f][2,1‐d:1′,2′‐f][1,3,2]dioxaphosphepine 4‐oxide (1h) Following the General Procedure E, subjection of triazolyl diol 6 h (1.48g, 1.27mmol, 1.0 eq.) and phosphorylchloride (0.78g, 5.08mmol, 4.0 eq.) with subsequent purification by column chromatography using CH2Cl2/MeOH (20:1) as eluent gave the title compound (750.6mg, 0.61mmol, 48%) as a brown solid. R f =0.49 (20:1) (SiO2, CH2Cl2/MeOH). 1H‐NMR (300MHz, CDCl3) δ[ppm]: 8.11 (s, 4H), 7.58 (s, 2H), 7.05 (s, 4H), 6.71 (s, 4H), 2.69 (s, 4H), 2.27 (s, 6H), 1.96 (s, 12H), 1.65 (s, 4H), 1.31 (bs, 60H), 0.91 (t, J =6.7 Hz, 6H). 13C‐NMR (75 MHz, CDCl3) δ[ppm]: 148.4, 144.9, 140.9, 140.6, 137.5, 137.3, 136.1, 130.3, 130.0, 128.8, 128.5, 128.3, 126.8, 126.4, 126.2, 125.8, 123.2, 35.6, 31.8, 30.8, 29.6, 29.5, 29.4, 29.2, 22.6, 20.9, 20.6, 14.0. 31P‐NMR (121 MHz, CDCl3) δ[ppm]: 1.69. HRMS (ESI): m/z [M−H]+ calcd for C78H107N6O4P+H: 1223.8164; found: 1223.8157. 2.8.9 N‐((4S,11bS)‐2,6‐Bis(4‐mesityl‐1H‐1,2,3‐triazol‐1‐yl)‐9,14‐dioctyl‐4‐oxidodinaphtho[2‐d:1′,2′‐f][2,1‐d:1′,2′‐f] [1,3,2]dioxaphosphepin‐4‐yl)‐1,1,1‐trifluoromethanesulfonamide (1c#) [27] To a solution of BINOL (1.2g, 1.4mmol, 1.0 eq.) in CH2Cl2 (7.0ml) were added Et3N (1.3ml, 9.6mmol, 6.9 eq.), POCl3 (0.16ml, 1.7mmol, 1.2 eq.) and DMAP (334mg, 2.7mmol, 2.0 eq.) at 0°C. After being stirred for 1h at room temperature, EtCN (7.0ml) and TfNH2 (0.5g, 3.4mmol, 2.4 eq.) were added at room temperature. The reaction mixture was stirred at 100°C and was allowed to cool to room temperature after 12h. The solution was quenched with H2O (15ml) and extracted with Et2O (2×15ml). The combined organic layers were washed with sat. aq. NaHCO3 (10ml), 4M HCl (2×10ml), dried over Na2SO4, filtered and the solvent was removed under reduced pressure. Purification of the crude product by column chromatography (PE/EA 4:1) gave the title compound (105.3mg, 0.01mmol, 7%) as a brown solid [along with the PA 1c (330.1mg, 0.35mmol, 25%)]. 1H‐NMR (300 MHz, CDCl3) δ[ppm]: 8.35 (s, 1H), 8.17 (s, 1H), 7.92–7.86 (m, 2H), 7.77 (d, J =5.9 Hz, 2H), 7.30 (t, J =9.3 Hz, 2H), 7.23 (s, 2H), 6.92 (s, 2H), 6.61 (s, 2H), 2.80–2.74 (m, 4H), 2.31 (s, 3H), 2.10 (s, 9H), 2.00 (s, 6H), 1.68 (s, 4H), 1.40–1.17 (m, 20H), 0.93–0.81 (m, 6H). 13C‐NMR (75 MHz, CDCl3) δ[ppm]: 145.1, 140.9, 137.8, 130.5, 130.3, 129.1, 128.4, 126.9, 126.7, 126.4, 126.3, 123.6, 35.7, 31.9, 31.0, 29.5, 29.3, 22.7, 21.1, 20.7, 14.2. 31P‐NMR (121 MHz, CDCl3) δ[ppm]: 3.55. HRMS (ESI): m/z [M+H]+ calcd for C59H68F3N7O5PS+H: 1074.4687; found: 1074.4680. 2.9 General procedure for the catalytic reaction The PA catalyst 1c (18.9mg, 0.02mmol, 10mol%) and Na3PO4 (50.9mg, 0.48mmol, 2.4 eq.) were dissolved in dry Et2O (8ml) and stirred for 30min until the catalyst was completely dissolved. Dihydroisoquinoline benzamide 2 (0.2mmol, 1.0 eq.) and oxidant AcNHT+BF4 − (132.0mg, 0.44mmol, 2.2 eq.) were added and the reaction mixture was stirred vigorously for 24h at room temperature. After this time, the reaction mixture was diluted with sat. aq. Na2SO3 (4 ml) and the contents were shaken. The mixture was extracted with EtOAc (3x 4 ml) and the combined organic layers were dried over Na2SO4, filtered and the solvent was removed under reduced pressure. The desired product was purified by column chromatography with a PE/EtOAc mixture as eluent. 2.9.1 5‐Benzyl‐4b,5,12,13‐tetrahydro‐6H‐isoquinolino[2,1‐a]quinazolin‐6‐one (3a) [13,16c] Following the General Catalytic Procedure, the reaction of benzamide 2a (68.5mg, 0.20mmol) provided, after column chromatography (PE/EtOAc, 4:1), the desired product (66.9mg, 0.19mmol, 99%, 78:22 e.r.) as a white solid. The scale-up reaction of 2a (342.5mg, 1.0mmol) and 1c (94.3mg, 0.1mmol, 10 mol%) in 40mL Et2O provided 3a (324.9mg, 95%) with a 70:30 e.r., and the recrystallization from CH2Cl2/hexane led to the product in 92:8 e.r (130.0mg, 40% of recrystallization). R f =0.35 (4:1) (SiO2, PE/EtOAc). 1H NMR (300MHz, CDCl3) δ 7.94 (dd, J =7.7, 1.3Hz, 1H), 7.34–7.22 (m, 7H), 7.19–7.09 (m, 2H), 7.02–6.96 (m, 1H), 6.83 (dd, J =13.6, 7.7Hz, 2H), 5.70 (bd, J =14.5Hz, 1H), 5.64 (s, 1H), 4.34 (d, J =15.3Hz, 1H), 3.97 (dd, J =14.2, 5.1Hz, 1H), 3.47 (ddd, J =14.2, 11.1, 5.7Hz, 1H), 3.16–2.98 (m, 1H), 2.67 (dd, J =17.0, 3.8Hz, 1H). 13C NMR (75MHz, CDCl3) δ 163.5, 147.5, 137.3, 134.9, 133.5, 129.6, 129.3, 128.7, 128.3, 127.7, 127.6, 126.3, 126.0, 119.5, 118.6, 113.7, 71.8, 49.8, 44.7, 24.6. HRMS (ESI): m/z [M+H]+ calcd for C23H20N2 +H: 341.1648; found: 341.1655. HPLC (Chiralpak IC column, 75:25 hexanes/isopropanol, 1 ml/min); tr =20.9 (minor), 25.0 (major) min. 2.9.2 5-(4-Chlorobenzyl)-4b,5,12,13-tetrahydro-6H-isoquinolino[2,1-a]quinazolin-6-one (3b) Following the General Catalytic Procedure, the reaction of benzamide 2b (40.2mg, 0.10mmol, 1.0 eq.) provided, after column chromatography (CH2Cl2), the desired product (30.0mg, 0.08mmol, 80%, 72:28 e.r.) as a white solid. R f =0.49 (SiO2, CH2Cl2). 1H NMR (300MHz, CDCl3) δ[ppm]: 7.96 (dd, J =7.7, 1.5Hz, 1H), 7.36 (ddd, J =8.7, 7.3, 1.6Hz, 1H), 7.28–7.14 (m, 8H), 7.06–7.01 (m, 1H), 6.93–6.83 (m, 2H), 5.65 (s, 1H), 5.55 (bs, 1H), 4.37 (d, J =15.5Hz, 1H), 4.04–3.90 (m, 1H), 3.50 (ddd, J =14.1, 10.9, 5.7Hz, 1H), 3.16–2.96 (m, 1H), 2.73 (ddd, J =16.9, 5.4, 2.4Hz, 1H). 13C‐NMR (75MHz, CDCl3) δ[ppm]: 163.7, 147.7, 136.0, 135.0, 133.6, 133.3, 132.4, 129.6, 129.4, 129.1, 128.8, 128.7, 128.5, 126.4, 126.2, 119.7, 114.0, 71.9, 48.9, 44.7, 24.9. HRMS (ESI): m/z [M+H]+ calcd for C23H20ClN2O+H: 375.1259; found: 375.1265. HPLC (Chiralpak IC column, 75:25 hexanes/isopropanol, 1 ml/min); tr =16.0 (minor), 22.0 (major) min. 2.9.3 5-(3,4-Dimethoxybenzyl)-4b,5,12,13-tetrahydro-6H-isoquinolino[2,1-a]quinazolin-6-one (3c) [16c] Following the General Catalytic Procedure, the reaction of benzamide 2c (37.7mg, 0.100mmol, 1.0 eq.) provided, after column chromatography (PE/EtOAc, 4:1→2:1), the desired product (32.4mg, 0.081mmol, 81%, 71:29 e.r.) as a pale yellow solid. R f =0.05 (4:1) (SiO2, PE/EtOAc). 1H NMR (300MHz, CDCl3) δ[ppm]: 7.95 (dd, J =7.7, 1.5Hz, 1H), 7.33 (ddd, J =8.7, 7.3, 1.6Hz, 1H), 7.29–7.24 (m, 2H), 7.22–7.12 (m, 2H), 7.05–6.98 (m, 1H), 6.91–6.73 (m, 5H), 5.65 (s, 2H), 4.31 (d, J =15.1Hz, 1H), 4.06–3.93 (m, 1H), 3.50 (ddd, J =14.2, 11.0, 5.8Hz, 1H), 3.19–3.03 (m, 1H), 2.71 (dd, J =17.0, 3.5Hz, 1H). 13C NMR (75MHz, CDCl3) δ[ppm]: 163.4, 149.1, 148.4, 147.4, 134.8, 133.4, 129.7, 129.5, 129.2, 128.2, 126.2, 126.0, 120.2, 119.4, 113.7, 111.0, 111.0, 71.3, 68.0, 55.9, 44.6, 25.6. HRMS (ESI): m/z [M+H]+ calcd for C25H25N2O3 +H: 401.1860; found: 401.1868. HPLC (Chiralpak IA column, 80:20 hexanes/isopropanol, 1 ml/min); tr =27.8 (major), 32.5 (minor) min. 2.9.4 5-((S)-1-Phenylethyl)-4b,5,12,13-tetrahydro-6H-isoquinolino[2,1-a]quinazolin-6-one (3d) Following the General Catalytic Procedure, the reaction of benzamide 2d (35.6mg, 0.100mmol, 1.0 eq.) provided, after column chromatography (PE/EtOAc, 4:1), the desired product (28.0mg, 0.079mmol, 79%, 68:32 d.r.) as a white solid. R f =0.42 (4:1) (SiO2, PE/EtOAc). 1H NMR (300MHz, CDCl3) δ[ppm]: 7.86 (d, J =7.8Hz, 1H major+1H minor), 7.57 (d, J =7.4Hz, 1H major+1H minor), 7.45 (d, J =7.5Hz, 1H major+1H minor), 7.42–7.22 (m, 5H major+5H minor), 7.16–7.07 (m, 1H major+1H minor), 7.05–6.66 (m, 3H major+5H minor), 6.48 (d, J =7.7Hz, 1H major), 6.17 (s, 1H minor), 6.05 (s, 1H major), 5.73 (s, 1H major), 5.54 (s, 1H minor), 4.21 (dd, J =14.4, 7.3Hz, 1H major), 4.15–4.04 (m, 1H minor), 3.83–3.66 (m, 1H major), 3.56–3.42 (m, 1H minor), 3.30–3.10 (m, 1H major+1H minor), 2.81–2.64 (m, 1H major+1H minor), 1.81 (d, J =7.1Hz, 3H major), 1.75 (d, J =7.3Hz, 3H, minor). 13C NMR (75MHz, CDCl3) δ[ppm]: 163.8, 147.3, 142.4, 133.4, 133.3, 129.7, 129.6, 129.2, 128.9, 128.8, 128.6, 128.5, 128.0, 127.5, 127.0, 126.4, 126.0, 125.5, 119.4, 119.0, 113.2, 69.3, 54.4, 53.3, 45.1, 44.7, 23.9, 18.9. HRMS (ESI): m/z [M+H]+ calcd for C24H22N2O+H: 355.1805; found: 355.1810. HPLC (Chiralpak IA column, 85:15 hexanes/isopropanol, 1 ml/min); tr =11.5 (minor), 16.3 (major) min. 2.9.5 4b,5,12,13-Tetrahydro-6H-isoquinolino[2,1-a]quinazolin-6-one (3e) [16a,b] Following the General Catalytic Procedure, the reaction of benzamide 2e (25.2mg, 0.100mmol, 1.0 eq.) provided, after column chromatography (PE/EtOAc, 3:1), the desired product (17.1mg, 0.041mmol, 41%, 60:40 e.r.) as a white solid. R f =0.07 (3:1) (SiO2, PE/EtOAc). 1H NMR (300MHz, CDCl3) δ[ppm]: 8.04 (dd, J =7.9, 1.6Hz, 1H), 7.49 (ddd, J =8.4, 7.4, 1.7Hz, 1H), 7.36–7.29 (m, 3H), 7.25–7.20 (m, 1H), 7.06–7.00 (m, 1H), 6.07 (bs, 1H), 5.73 (s, 1H), 3.92–3.84 (m, 1H), 3.29–3.19 (m, 1H), 3.17–3.11 (m, 1H), 3.04–2.94 (m, 1H). The analytical data are in accordance with the literature. HPLC (Chiralpak IC column, 75:25 hexanes/isopropanol, 1 ml/min); tr =18.0 (major), 20.2 (minor) min. 2.9.6 5-Cyclohexyl-4b,5,12,13-tetrahydro-6H-isoquinolino[2,1-a]quinazolin-6-one (3f) [13,16c] Following the General Catalytic Procedure, the reaction of N-alkyl benzamide 2f (33.4mg, 0.100mmol, 1.0 eq.) provided, after column chromatography (CH2Cl2), the desired product (7.6mg, 0.023mmol, 23%, 59:41 e.r.) as a white solid. R f =0.28 (4:1) (SiO2, CH2Cl2). 1H NMR (300MHz, CDCl3) δ[ppm]: 7.83 (dd, J =7.7, 1.6Hz, 1H), 7.37–7.32 (m, 1H), 7.29–7.22 (m, 2H), 7.15–7.04 (m, 2H), 7.01–6.94 (m, 1H), 6.85 (d, J =8.2Hz, 1H), 6.81–6.71 (m, 1H), 5.65 (s, 1H), 4.66 (bs, 1H), 4.22 (dd, J =14.8, 7.1Hz, 1H), 3.79 (ddd, J =14.8, 11.4, 6.5Hz, 1H), 3.34–3.17 (m, 1H), 2.78 (dd, J =17.3, 6.2Hz, 1H), 2.17 (d, J =10.3Hz, 1H), 2.04 (d, J =11.2Hz, 1H), 1.93–1.76 (m, 2H), 1.74–1.63 (m, 2H), 1.61–1.37 (m, 3H), 1.21–1.04 (m, 1H). 13C NMR (75MHz, CDCl3) δ[ppm]: 163.4, 147.1, 137.6, 134.4, 133.2, 129.5, 129.1, 127.9, 126.6, 125.9, 119.6, 119.2, 113.2, 68.9, 54.6, 45.0, 32.5, 30.9, 26.0, 25.6, 23.8. HRMS (ESI): m/z [M+H]+ calcd for C22H24N2O+H: 333.1961; found: 333.1969. HPLC (Chiralpak IC column, 75:25 hexanes/isopropanol, 1 ml/min); tr =15.5 (major), 17.4 (minor) min. 2.9.7 5-(2-Chlorophenyl)-4b,5,12,13-tetrahydro-6H-isoquinolino[2,1-a]quinazolin-6-one (3g) [13] Following the General Catalytic Procedure, the reaction of N-aryl benzamide 2 g (36.3mg, 0.10mmol, 1.0 eq.) provided, after column chromatography (CH2Cl2), the desired product (5.1 mg, 0.14 mmol, 14%, 50:50 e.r.) as a white solid. R f =0.26 (4:1) (SiO2, CH2Cl2). 1H NMR (300MHz, CDCl3) δ[ppm]: 8.09 (dd, J =8.0, 1.6Hz, 1H), 7.49–7.42 (m, 1H), 7.42–7.36 (m, 1H), 7.11–7.02 (m, 5H), 6.99–6.89 (m, 2H), 6.87–6.70 (m, 2H), 6.17 (s, 1H), 3.94–3.83 (m, 1H), 3.47 (dt, J =12.0, 5.9Hz, 1H), 3.20–2.96 (m, 2H). 13C‐NMR (75MHz, CDCl3) δ[ppm]: 164.8, 149.6, 141.3, 136.8, 134.9, 133.7, 130.8, 129.9, 129.6, 129.5, 129.2, 128.8, 128.5, 127.1, 125.9, 121.9, 118.1, 72.4, 45.4, 28.7. HRMS (ESI): m/z [M+H]+ calcd for C22H17ClN2O+H: 361.1102; found: 361.1110. HPLC (Chiralpak IC column, 75:25 hexanes/isopropanol, 1 ml/min); tr =30.1, 43.5min. 2.9.8 4b,13-Dihydro-6H,12H-benzo[4,5][1,3]oxazino[2,3-a]isoquinolin-6-one (3h) [16a,c] Following the General Catalytic Procedure, the reaction of the carboxylic acid 2 h (25.3mg, 0.100mmol, 1 eq.) provided, after column chromatography (PE/EtOAc, 4:1), the desired product (15.6mg, 0.062mmol, 62%) as a pale yellow solid. R f =0.55 (4:1) (SiO2, PE/EtOAc). 1H NMR (300MHz, CDCl3) δ[ppm]: 8.09–8.05 (m, 1H), 7.56–7.50 (m, 2H), 7.35–7.26 (m, 2H), 7.24–7.17 (m, 2H), 7.11–7.04 (m, 2H), 6.12 (s, 1H), 3.71 (dt, J =12.0, 6.0Hz, 1H), 3.50–3.38 (m, 2H), 3.07 (t, J =5.9Hz, 2H). 13C NMR (75MHz, CDCl3) δ[ppm]: 165.2, 150.1, 135.3, 134.8, 131.1, 130.1, 129.5, 128.7, 128.5, 127.1, 122.2, 117.4, 117.1, 85.9, 43.8, 29.1. The analytical data are in accordance with the literature. 2.9.9 6,6-Dimethyl-4b,13-dihydro-6H,12H-benzo[4,5][1,3]oxazino[2,3-a]isoquinoline (3i) Following the General Catalytic Procedure, the reaction of the alcohol 2i (26.7mg, 0.100mmol, 1.0 eq.) provided, after column chromatography (PE/EtOAc, 32:1), the desired product (16.8mg, 0.063mmol, 63%, 54:46 e.r.) as a white solid. R f =0.32 (32:1) (SiO2, PE/EtOAc). 1H NMR (300MHz, CDCl3) δ[ppm]: 7.42–7.36 (m, 1H), 7.29–7.26 (m, 2H), 7.26–7.23 (m, 1H), 7.23–7.14 (m, 3H), 7.11 (dd, J =8.1, 0.9Hz, 1H), 7.04–6.96 (m, 1H), 5.50 (s, 1H), 3.59 (td, J =11.2, 3.7Hz, 1H), 3.41 (ddd, J =11.5, 5.3, 3.6Hz, 1H), 3.18 (ddd, J =16.1, 11.2, 5.3Hz, 1H), 2.94 (dt, J =16.0, 3.6Hz, 1H), 1.76 (s, 3H), 1.57 (s, 3H). 13C NMR (75MHz, CDCl3) δ[ppm]: 135.6, 135.4, 133.9, 128.8, 128.5, 128.1, 127.2, 126.5, 126.1, 122.1, 122.0, 116.6, 79.0, 76.0, 46.1, 31.9, 29.9, 29.2. HRMS (ESI): m/z [M+H]+ calcd for C18H19NO + H: 265.1467; found: 265.1472. HPLC (Chiralpak OD-H column, 90:10 hexanes/isopropanol, 1 ml/min); tr =4.0 (major), 4.4 (minor) min. 2.9.10 6,7,11b,12-Tetrahydro-13H-isoquinolino[2,1-a]quinolin-13-one (3j) [16] Following the General Catalytic Procedure, the reaction of the ketone 2 j (25.0mg, 0.10mmol, 1.0 eq.) provided, after column chromatography (PE/EtOAc, 9:1), the desired product (13.0mg, 0.052mmol, 52%, 58:42 e.r.) as a yellow solid. R f =0.14 (9:1) (SiO2, PE/EtOAc). 1H NMR (300MHz, CDCl3) δ[ppm]: 8.01 (dd, J =7.9, 1.6Hz, 1H), 7.50–7.46 (m, 1H), 7.32–7.29 (m, 1H), 7.28–7.15 (m, 3H), 7.02 (d, J =8.6Hz, 1H), 6.84 (t, J =7.4Hz, 1H), 4.76 (dd, J =13.7, 2.5Hz, 1H), 4.19–4.05 (m, 1H), 3.29–3.05 (m, 3H), 2.99–2.90 (m, 1H), 2.84–2.75 (m, 1H). The analytical data are in accordance with the literature. HPLC (Chiralpak OJ-H column, 85:15 hexanes/isopropanol, 1 ml/min); tr =4.8 (major), 5.1 (minor) min. 3 Results and discussion Initially, a small family of Click-BINOL-derived chiral phosphoric acids 1 was synthetized (Scheme 2 ). Thus, starting from commercially available (S)-BINOL, we employed our early procedure for the preparation of the 3,3′-diazido BINOL derivative 4, [15a] which implies a first MOM protection and an ortho-directed lithiation/substitution sequence. Subsequent copper-catalyzed alkyne-azide cycloaddition reaction (CuAAC) and MOM-deprotection led to the corresponding Click-BINOLs 6a and b. Finally, phosphorylation with phosphoryl trichloride and acid work-up delivered the desired phosphoric acids 1a and 1b, bearing a phenyl and a mesityl group at the triazole units, respectively. Similarly, 6,6′-alkyl substituted BINOL-diazides 11–13 were easily prepared in gram scale. The direct bromination of (S)-BINOL and reaction with MOM-chloride led to the corresponding dibromo-BINOL 7, which was subjected to a Kumada cross-coupling with octyl, dodecyl and octadecyl magnesium bromide [13] and subsequent azide formation. CuAAC with various bulky aryl (Mes, mesityl; Trip, 2,4,6-triisopropylphenyl; BDIP, 4-bromo-2,6-diisopropylphenyl) and alkyl (Ad, 1-adamatyl) substituted terminal alkynes followed by MOM-deprotection and phosphorylation, provided the catalysts 1c-h in moderate to good overall yields. Finally, under non-optimized conditions, the more acidic triflamide derivative 1c# was also prepared from the corresponding BINOL 6c. In order to investigate the importance and effect of the triazole units on the catalytic activity of these new Click-PA catalysts, we next decided to explore them in the intramolecular asymmetric CH functionalization of tetrahydroisoquinoline-N-benzamides, previously studied by Toste and co‐workers [13]. Therefore, the reaction with benzamide 2a in the presence of our catalysts was first optimized (Table 1 ). It is important to note the strong background reaction with this type of THIQ-N-benzamine substrates 2 (entry 1). Consequently, in order to achieve high enantioselectivities a potent catalyst would be required. Therefore, the start point of our study was the screening of the catalysts 1a–e under analogous reported conditions: Na3PO4 as base to form in situ the active phosphate catalyst and a TEMPO oxoammonium salt (AcNHT+BF4 −) as oxidant in toluene (dilution 0.025M) as apolar solvent to favor the formation of close ion-pairs at room temperature (entries 2–6). Already with the simplest catalysts 1a and b, the effect of the substitution at the triazole rings could be observed. Thus, an inversion on the enantioselectivity was detected when replacing a phenyl for a bulkier mesityl group (entries 2 and 3). The introduction of a linear C8-alkylic chain in the BINOL-backbone was beneficial, leading to 3a in an improved enantiomeric ratio (1c, 66:34 e.r., entry 4). Similar results were obtained with the catalysts 1d and e bearing bulkier Trip and Ad groups, respectively (entries 5–6). The screening of solvents was next carried out with 1c. As expected the solvent had an important effect on the enantioselectivity of the reaction. Whereas p-xylene showed a slightly higher enantioinduction (70:30 e.r., entry 7), ethereal solvents such as simple Et2O provided the best results (78:22 e.r., entry 9). The performance of the triflamide derivative 1c# and the catalysts 1d-f was also tested in Et2O as solvent (entries 10–13). Nevertheless, they were inferior to the mesityl-subtituted catalyst 1c. Considering the presumable positive effect of the octyl chains by enhancing the catalyst’s solubility in the used apolar solvents, other structures with longer alkyl rests such as dodecyl (1 g) and octadecyl (1 h) were then investigated (entries 14 and 15). Conversely, the shorter n-octyl chain in 1c remained superior and this PA was further employed as catalyst of choice. Next, various inorganic bases such as phosphates and carbonates, and ionic hydride abstractors or oxidants such as TEMPO and trityl salt derivatives were explored (entries 16–20). However, the initially employed mixture of salts (AcNHT+BF4 −and Na3PO4) gave the higher enantioselectivity. It was also observed that the decrease in the temperature (-20 and −40°C, entries 21 and 22) was not beneficial, leading to less efficient asymmetric reactions. Lastly, the use of lower catalytic loadings (5 and 2.5 mol%, entries 23 and 24) was also translated in a gradual decrease of the enantioinduction. The substitution and nature of the nucleophile was then studied with our identified optimal reaction conditions: 10 mol% of catalyst 1c, Na3PO4 as base, AcNHT+BF4 − as oxidant in Et2O at room temperature (Scheme 3 ). Differently benzyl-substituted benzamides 2 led to the corresponding quinazolinones 3a-c in comparable moderate enantioselectivities (71:29–78:22 e.r.). Moreover, the reaction with a chiral substrate 2d provided a similar level of diastereoselectivity (3d, 63:27 d.r.), which turned out to be opposite to the one obtained in the uncatalyzed reaction (22:68 d.r.). Unexpectedly, a change in the nature of the nucleophilic unit on the substrate from a N-benzyl benzamide to an unsubstituted (NH2, 2e), N-alkyl (cyclohexyl, 2f) or N-aryl (2-chlorophenyl, 2 g) benzamide proceeded to the expected products 3e-g, although in inferior yields and low or imperceptible enantioselectivities. Moreover, the formation of CO or CC bonds by reaction of the carboxylic acid 2 h and tertiary alcohol 2i or methyl ketone 2 j also took place, leading to the corresponding products in similar low enantiomeric inductions. It is important to mention that the reaction could be scaled-up 5 times to a 1.0mmol scale, leading to only a slightly detriment to the enantioselectivity. Thus, the reaction with 2a (>340mg) provided the quinazolinone product 3a in a good 95% yield and 70:30 e.r. Furthermore, we observed that the racemic compounds 3 possess a high crystallinity, allowing reaching extremely high enantioselectivities (up to 99:1 e.r. for 3a) by the simple recrystallization (by removal of the racemic crystals from the product of the catalytic reactions). Consequently, in order to avoid getting incorrect e.r. values, acetonitrile was used to completely dissolve the probes for the HPLC analyses [28]. Lastly, a comparison of the effectiveness of our developed chiral Click-BINOL-PA catalysts 1 with commercially available derivatives and the previously reported regioisomeric triazole-BINOL-PA 1C’ in the model asymmetric CH bond functionalization reaction of benzamide 2a was carried out (Fig. 2 ). The presence of the triazole groups is crucial to achieve enantiomeric induction. Thus, standard chiral phosphoric acids such as TRIP® provided the racemic product, while the Click-BINOL-PAs 1c and 1C’ showed certain levels of enantioselectivity. In this regard, our best Click-BINOL-PA catalysts 1c afforded a moderate enantioselectivity (78:22 e.r.), while the catalyst 1C’, which only differ in the rearrangement of the triazole units, led to an enhanced enantiomeric ratio value (89:11 e.r.). The fact that the reaction with N-benzylic amides provided the best enantiomeric results might be explained by the already proposed essential π−π interaction between the triazole ring of the catalyst 1C’ and related structures and the benzylic substituent at the benzylamide [13b]. However, the observation of a match/mismatch effect depending on the regioisomeric triazoles employed suggest an additional positive interaction of the triazole units with the substrate and/or ionic iminium intermediate, which might facilitate the effective formation of the required chiral close ion-pair. Furthermore, the spatial disposition of the substituents on the triazoles in 1C’ permitted a torsion angle of 90° in the transition state, which was proposed to be also key for attaining high enantioinductions [13b]. A simplified plausible mechanism is shown in Scheme 3, in which the key step to form a close ion-pair B and allow chirality transfer is the counter-anion exchange between the active Click-phosphate catalyst I and the iminium intermediate A (pathway A) and/or ionic oxidant (AcNHT+BF4 −) (pathway B). Aiming at gaining more information on the counter-anion exchange, a reaction using stoichiometric amounts of the phosphoric acid 1c was made (Scheme 4 ). For this purpose, the Click-BINOL-PA 1c, the base and the oxidant were reacted for 20min before adding the substrate 2a. Under these conditions, the same 78:22 enantiomeric ratio was obtained, showing that the anion exchange was as effective in the catalytic as in the stoichiometric reaction. 4 Conclusions To sum up, new chiral triazole-containing phosphoric acids have been developed and employed as catalysts for the intramolecular enantioselective oxidative CH bond functionalization of tetrahydroisoquinolines. The presence of the triazole groups on the catalysts was key to achieve the transfer of chirality to the products. Moderate enantioselectivities were obtained with the THIQ-N-benzamide substrates, whereas the related regioisomeric catalysts seemed to be more effective for this transformation. The formation of a chiral close ion-pair between the phosphate catalyst and the iminium ion intermediate, which stays in equilibrium with the achiral species, is essential for success. Therefore, the design of further superior catalyst structures is still needed to attain elevated enantioselectivities in further asymmetric CH bond functionalization reactions that relies on counter-anion organocatalysis. Acknowledgements The Deutsche Forschungsgemeinschaft (DFG) is gratefully acknowledged for financial support. D. G. thanks the Deutscher Akademischer Austauschdienst (DAAD) and the University of Regensburg for an iPur PhD-exchangefellowship. Appendix A Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.molcata.2016.09.006. Appendix A Supplementary data Electronic Supplementary information (ESI) is available: Procedures and characterization of starting materials; NMR and HPLC collection of new compounds. The following are Supplementary data to this article: References [1] (a) Pioneer work on CDC: Z.-P. Li C.-J. Li J. Am. Chem. Soc. 126 2004 11810 (b) Z.-P. Li C.-J. Li J. Am. Chem. Soc. 127 2005 3672 [2] (b) G. Dyker Handbook of CH Transformations 2005 Wiley-VCH Weinheim Overviews on CH activation and functionalization: F. Kakiuchi, S. Murai, Activation of Unreactive Bonds and Organic Synthesis In Topics in Organometallic Chemistry, 1999, vol. 3; (c) J.-Q. Yu Z.J. Shi Topics in Current Chemistry vol. 292 2010 Springer [3] (a) Selected reviews: C.J. Scheuermann Chem. Asian J. 5 2010 436 (b) M. Klussmann D. Sureshkumar Synthesis 3 2011 353 (c) C.S. Yeung V.M. Dong Chem. Rev. 111 2011 1215 (d) C. Liu H. Zhang W. Shi A. Lei Chem. Rev. 111 2011 1780 (e) R. Rohlmann O. García Mancheño Synlett 24 2013 6 (f) S.A. Girard T. Knauber C.J. Li Angew. Chem. Int. Ed. 53 2014 74 (g) R. Narayan K. Matcha A.P. Antonchick Chem. Eur. J. 21 2015 14678 (h) H.M.L. Davies D. Morton J. Org. Chem. 81 2016 343 (i) J.F. Hartwig A.A. Larsen ACS Cent. Sci. 2 2016 281 and references cited therein [4] (a) Recent a review on asymmetric couplings of α− C(sp3)-H of amines: Y. Qin J. Lv S. Luo Tetrahedron Lett. 55 2014 551 See also: (b) W. Liu S. Liu R. Jin H. Guo J. Zhao Org. Chem. Front. 2 2015 288 For a mechanistic study, see: (c) E. Boess C. Schmitz M. Klussmann J. Am. Chem. Soc. 134 2012 5317 [5] (a) Pioneer work on TEMPO salts as oxidants in CH functionalization: H. Richter O. García Mancheño Eur. J. Org. Chem. 2010 4460 (See also:) (b) H. Richter O. García Mancheño Org. Lett. 13 2011 6066 (c) H. Richter R. Rohlmann O. García Mancheño Chem. Eur. J. 17 2011 11622 (d) H. Richter R. Fröhlich C.G. Daniliuc O. García Mancheño Angew. Chem. Int. Ed. 51 2012 8656 (e) R. Rohlmann T. Stopka H. Richter O. García Mancheño J. Org. Chem. 78 2013 6050 For oxidative CH functionalization/ring expansion using benzoylperoxide as oxidant: (f) T. Stopka L. Marzo M. Zurro S. Janich E.-U. Würthwein C.G. Daniliuc J. Alemán O. García Mancheño Angew. Chem. Int. Ed. 54 2015 5049 [6] (a) Reviews on N-oxoammonium chemistry: J.M. Bobbitt M.C.L. Flores Heterocycles 27 1988 509 (b) J.M. Bobbitt C. Brückner N. Merbouh S.E. Denmark Oxoammonium- and nitroxide-catalyzed oxidations of alcohols In Org. Reactions vol. 74 2009 Wiley New York pp 103 (c) T. Stopka O. García Mancheño Synthesis 45 2013 1602 See also: (d) M.A. Mercadante C.B. Kelly J.M. Bobbitt L.J. Tilley N.E. Leadbeater Nat. Protoc. 8 2013 666 (e) T.A. Hamlin C.B. Kelly J.M. Ovian R.J. Wiles L.J. Tilley N.E. Leadbeater J. Org. Chem. 80 2015 8150 [7] (a) For further examples in CH functionalization, see for example: S. Wetz S. Kodama A. Studer Angew. Chem. Int. Ed. 50 2011 11511 (b) C. Yan Y. Liu Q. Wang RSC Adv. 4 2014 60075 (c) S. Sun C. Li P.E. Floreancig H. Lou L. Liu Org. Lett. 17 2015 1684 [8] (a) Pioneer work: Z. Li C.-J. Li Org. Lett. 6 2004 4997 Recent reviews: (b) Y. Qin J. Lv S. Luo Tetrahedron Lett. 55 2014 551 (c) C. Zheng S.-L. You RSC Adv. 4 2014 6173 (d) W. Liu S. Liu R. Jin H. Guo J. Zhao Org. Chem Front. 2 2015 288 [9] (a) See for example: N. Sasamoto C. Dubs Y. Hamashima M. Sodeoka J. Am. Chem. Soc. 128 2006 14010 (b) O. Basléand C.-J. Li Org. Lett. 10 2008 3661 (c) G. Zhang Y. Zhang R. Wang Angew. Chem. Int. Ed. 50 2011 10429 (d) W. Cao X. Liu R. Peng P. He L. Lin X. Feng Chem. Commun. 49 2013 3470 (e) J. Yu Z. Li K. Jia Z. Jiang M. Liu W. Su Tetrahedron Lett. 54 2013 2006 (f) I. Perepichka S. Kundu Z. Hearne C.-J. Li Org. Biomol. Chem. 13 2015 447 and references cited herein. [10] (a) For recent overviews, see: Y.-L. Zhao Y. Wang Y.-C. Luo X.-Z. Fu P.-F. Xu Tetrahedron Lett. 56 2015 3703 (b) S. Stockerl O. García Mancheño Org. Chem. Front. 3 2016 277 For the initial studies: (c) K.C. Nicolaou R. Reingruber D. Sarlah S. Bräse J. Am. Chem. Soc. 131 2009 2086 (d) J.C. Conrad J. Kong B.N. Laforteza D.W.C. MacMillan J. Am. Chem. Soc. 131 2009 11640 See also: (e) F. Benfatti M.G. Capdevila L. Zoli E. Benedetto G. Cozzi Chem. Commun. 2009 5919 (f) X.H. Ho S.I. Mho H. Kang H.Y. Jang Eur. J. Org. Chem. 2010 4436 (g) B. Zhang S.K. Xiang L.H. Zhang Y.X. Cui N. Jiao Org. Lett. 13 2011 5212 (h) J. Zhang B. Tiwari C. Xing X. Chen Y.G. Chi Angew. Chem. Int. Ed. 51 2012 3649 (i) Z.L. Meng S.T. Sun H.Q. Yuan H.X. Lou L. Liu Angew. Chem. Int. Ed. 53 2014 553 (j) Y. Ma G. Zhang D. Yang R. Wang Org. Lett. 16 2014 5358 (k) X. Liu S. Sun Z. Meng H. Lou L. Liu Org. Lett. 17 2015 2396 [11] (a) Selected recent reviews: M. Mahlau B. List Angew. Chem. Int. Ed. 52 2013 518 (b) K. Brak E.N. Jacobsen Angew. Chem. Int. Ed. 52 2013 534 (c) S. Beckendorf S. Asmus O. García Mancheño ChemCatChem 4 2012 926 [12] (a) Selected reviews: T. Akiyama Chem. Rev. 107 2007 5744 (b) M. Terada Synthesis 12 2010 1929 (c) R.J. Phipps G.L. Hamilton D.F. Toste Nature Chem. 4 2012 603 (d) D. Parmar E. Sugiono S. Raja M. Rueping Chem. Rev. 114 2014 9047 [13] (a) A.J. Neel J.P. Hehn P.F. Tripet F.D. Toste J. Am. Chem. Soc 135 2013 14044 (b) A. Milo A.J. Neel F.D. Toste Science 347 2015 737 [14] G. Bergonzini C.S. Schindler C.-J. Wallentin E.N. Jacobsen C.R.J. Stephenson Chem. Sci. 5 2014 112 [15] (a) S. Beckendorf O. García Mancheño Synthesis 44 2012 2162 For just the synthesis of regioisomeric phosphoramidites, see: (b) C. Recsei S.P. McErlean Tetrahedron 68 2012 464 For 1,2,4-triazole-BINOLs, see: (c) B. Liu F.-Y. Jiang H.-B. Song J.-S. Li Tetrahedron: Asymmetry 17 2006 2149 [16] (a) For related non-asymmetric methods, see: W.-P. To Y. Liu T.-C. Lau C.-M. Che Chem. Eur. J. 19 2013 5654 (b) C. Huo M. Wu X. Jia H. Xie Y. Yuan J. Tang J. Org. Chem. 79 2014 9860 (c) Y. Liu D. Zhang-Negrerie K. Zhao Y. Du J. Org. Chem. 81 2016 3372 [17] H.E. Gottlieb V. Kotlyar A. Nudelman J. Org. Chem. 62 1997 7512 [18] D. Casarini L. Lunazzi A. Mazzanti J. Org. Chem. 73 2008 2811 [19] J. Bouffard B.K. Keitz R. Tonner V. Lavallo G. Guisado-Barrios G. Frenking R.H. Grubbs G. Bertrand Organometallics 30 2011 2617 [20] Y. Chen A. Wang Z. Tao Y. Deng X. Hu Lett. Org. Chem. 11 2014 627 [21] M. Busch M. Schlageter D. Weingand T. Gehring Chem. Eur. J. 15 2009 8251 [22] (a) M. Basauri-Molina D.G.A. Verhoeven A.J. van Schaik H. Kleijn R.J.M. Klein Gebbink Chem. Eur. J. 21 2015 15676 [23] T. Fujihara Y. Tomike T. Ohtake J. Terao Y. Tsuni Chem. Commun. 48 2011 9699 [24] C.P.J. Schubert M.G. Tamba G.H. Mehl Chem. Commun. 48 2012 6851 [25] H. Ishitani M. Ueno S. Kobayashi J. Am. Chem. Soc. 122 2000 8180 [26] D. Ishikawa T. Mori Y. Yonamine W. Nakanishi D.L. Cheung J.P. Hill K. Ariga Angew. Chem. Int. Ed. 54 2015 8988 [27] D. Nakashima H. Yamamoto J. Am. Chem. Soc. 128 2006 9626 [28] False positive high enantioselectivities (>90:10 e.r. for 3a) were obtained at the beginning of the study since the racemic compound was crystallized-out in the HPLC vials when dissolving the probes in a 90:10 hexane/iPrOH mixture, thus enhancing the e.r. in solution.",
      "scopus-id": "84997416712",
      "coredata": {
        "eid": "1-s2.0-S1381116916303788",
        "dc:description": "Counteranion-catalysis represents an appealing but challenging approach for the development of enantioselective oxidative CH bond functionalization reactions. In this work, a new family of 3,3′-triazolyl BINOL-derived phosphoric acids was synthesized and employed in the intramolecular asymmetric CH bond functionalization of N-aryl substituted tetrahydroisoquinolines. As previously reported with related structures, the presence of the triazole groups on the catalysts was key to attain enantioselectivity. Our study also shows the importance of choosing the appropriate regioisomeric triazole groups at the BINOL backbone to achieve a more efficient chirality transfer. Moderate enantiomeric ratios were obtained with the N-benzamide substrates, whereas the change of the nature of the nucleophile fragment was translated to a dramatic loss of the enantioselectivity. Therefore, it can be foreseen that there is a need for designing further superior catalyst structures to develop future counter-anion organocatalyzed asymmetric CH bond functionalization reactions.",
        "openArchiveArticle": "false",
        "prism:coverDate": "2017-01-31",
        "openaccessUserLicense": null,
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/article/pii/S1381116916303788",
        "dc:creator": [
          {
            "@_fa": "true",
            "$": "Stockerl, Sebastian"
          },
          {
            "@_fa": "true",
            "$": "Gutiérrez, Daniel"
          },
          {
            "@_fa": "true",
            "$": "García Mancheño, Olga"
          }
        ],
        "link": [
          {
            "@_fa": "true",
            "@rel": "self",
            "@href": "https://api.elsevier.com/content/article/pii/S1381116916303788"
          },
          {
            "@_fa": "true",
            "@rel": "scidir",
            "@href": "https://www.sciencedirect.com/science/article/pii/S1381116916303788"
          }
        ],
        "dc:format": "application/json",
        "openaccessType": null,
        "pii": "S1381-1169(16)30378-8",
        "prism:volume": "426",
        "prism:publisher": "Elsevier B.V.",
        "dc:title": "Click-binol-phosphoric acid catalysts in intramolecular enantioselective oxidative CH-bond functionalization",
        "prism:copyright": "© 2016 Elsevier B.V. All rights reserved.",
        "prism:issueName": "C–H Functionalization in Modern Molecular Catalysis",
        "openaccess": "0",
        "prism:issn": "13811169",
        "dcterms:subject": [
          {
            "@_fa": "true",
            "$": "CH functionalization"
          },
          {
            "@_fa": "true",
            "$": "Oxidation"
          },
          {
            "@_fa": "true",
            "$": "Organocatalysis"
          },
          {
            "@_fa": "true",
            "$": "Enantioselective"
          },
          {
            "@_fa": "true",
            "$": "Heterocycles"
          }
        ],
        "openaccessArticle": "false",
        "prism:publicationName": "Journal of Molecular Catalysis A: Chemical",
        "openaccessSponsorType": null,
        "prism:pageRange": "572-585",
        "prism:endingPage": "585",
        "pubType": "fla",
        "prism:coverDisplayDate": "January 2017",
        "prism:doi": "10.1016/j.molcata.2016.09.006",
        "prism:startingPage": "572",
        "dc:identifier": "doi:10.1016/j.molcata.2016.09.006",
        "openaccessSponsorName": null
      },
      "objects": {
        "object": [
          {
            "@category": "thumbnail",
            "@height": "164",
            "@width": "201",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-fx1.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "4523",
            "@ref": "fx1",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "164",
            "@width": "201",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-fx2.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "3741",
            "@ref": "fx2",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "164",
            "@width": "172",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-gr1.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "6287",
            "@ref": "gr1",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "126",
            "@width": "219",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-gr2.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "7743",
            "@ref": "gr2",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "126",
            "@width": "219",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-sc1.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "6637",
            "@ref": "sc1",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "161",
            "@width": "219",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-sc2.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "9247",
            "@ref": "sc2",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "164",
            "@width": "141",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-sc3.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "5765",
            "@ref": "sc3",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "164",
            "@width": "166",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-sc4.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "4554",
            "@ref": "sc4",
            "@mimetype": "image/gif"
          },
          {
            "@category": "standard",
            "@height": "245",
            "@width": "301",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-fx1.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "10070",
            "@ref": "fx1",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "standard",
            "@height": "245",
            "@width": "301",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-fx2.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "9281",
            "@ref": "fx2",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "standard",
            "@height": "304",
            "@width": "320",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-gr1.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "26505",
            "@ref": "gr1",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "standard",
            "@height": "280",
            "@width": "489",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-gr2.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "40996",
            "@ref": "gr2",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "standard",
            "@height": "282",
            "@width": "489",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-sc1.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "39303",
            "@ref": "sc1",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "standard",
            "@height": "497",
            "@width": "678",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-sc2.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "83947",
            "@ref": "sc2",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "standard",
            "@height": "567",
            "@width": "489",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-sc3.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "62886",
            "@ref": "sc3",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "standard",
            "@height": "483",
            "@width": "489",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-sc4.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "46117",
            "@ref": "sc4",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "high",
            "@height": "1085",
            "@width": "1333",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-fx1_lrg.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-HIGH-RES",
            "@size": "83703",
            "@ref": "fx1",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "high",
            "@height": "1085",
            "@width": "1333",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-fx2_lrg.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-HIGH-RES",
            "@size": "63859",
            "@ref": "fx2",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "high",
            "@height": "1347",
            "@width": "1417",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-gr1_lrg.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-HIGH-RES",
            "@size": "186602",
            "@ref": "gr1",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "high",
            "@height": "1243",
            "@width": "2167",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-gr2_lrg.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-HIGH-RES",
            "@size": "282416",
            "@ref": "gr2",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "high",
            "@height": "1250",
            "@width": "2167",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-sc1_lrg.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-HIGH-RES",
            "@size": "269428",
            "@ref": "sc1",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "high",
            "@height": "2201",
            "@width": "3000",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-sc2_lrg.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-HIGH-RES",
            "@size": "685141",
            "@ref": "sc2",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "high",
            "@height": "2514",
            "@width": "2167",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-sc3_lrg.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-HIGH-RES",
            "@size": "428766",
            "@ref": "sc3",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "high",
            "@height": "2139",
            "@width": "2167",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-sc4_lrg.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-HIGH-RES",
            "@size": "320268",
            "@ref": "sc4",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "standard",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116916303788-mmc1.pdf?httpAccept=%2A%2F%2A",
            "@multimediatype": "Acrobat PDF file",
            "@type": "APPLICATION",
            "@size": "9506577",
            "@ref": "mmc1",
            "@mimetype": "application/pdf"
          }
        ]
      },
      "link": {
        "@rel": "abstract",
        "@href": "https://api.elsevier.com/content/abstract/scopus_id/84997416712"
      }
    }
  }
}